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ABSTRACT 
The rapid increase in the prevalence of atopic diseases, such as asthma, allergic 
rhinitis and atopic eczema, over the recent decades suggests that environmental 
factors might play an important role in the pathogenesis of these diseases. According 
to the ‘hygiene hypothesis’, changes in the environmental microbial load and reduced 
microbial exposure during childhood, lead to an imbalance in the developing 
immune system and subsequently increase the risk of atopic diseases. The atopic 
reaction pattern often develops during early childhood, possibly already during the 
fetal period, suggesting that very early microbial contacts might be particularly 
important in the development of these diseases. Enteroviruses are common 
pathogens in childhood and previous studies have suggested an association between 
enterovirus infections and atopic diseases.  
The aim of this study was to investigate the relations between early enterovirus 
infections and atopy. Enteroviruses were analyzed from serum and stool samples 
collected prospectively from children developing atopy and from non-atopic 
controls. In addition, the relationship between maternal enterovirus infections 
during pregnancy and the risk of atopic disease in the offspring was addressed.  
The number of infections caused by different enterovirus types during early 
childhood was determined by analyzing neutralizing antibodies. Neutralizing 
antibodies against 12 different enterovirus types were measured and grouped as 
echoviruses and coxsackieviruses. The study showed that atopic case children had 
significantly fewer echovirus infections during the first two years of life than the 
non-atopic control children did. This finding supports previous data from cross-
sectional studies suggesting an inverse relationship between echovirus infections and 
atopy.  
Maternal enterovirus infection during pregnancy was diagnosed by an increase in 
the enterovirus antibody levels between serum samples drawn at the end of the first 
trimester of pregnancy and at birth. The results showed that mothers whose children 
later developed atopic diseases had significantly fewer enterovirus infections during 
pregnancy. No difference was observed between other microbial infections 
(influenza virus A, Mycoplasma pneumoniae, cytomegalovirus, Helicobacter pylori) and 
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atopy in the offspring. The relation between gestational enterovirus infections and 
atopy has not been studied previously.  
In addition, the association between enteroviruses present in stool samples 
collected during the first year of life and atopic sensitization was studied. This study 
included rhinoviruses, belonging to the Enterovirus genus, enteroviruses, noroviruses 
and parechoviruses. Atopic sensitization was inversely associated with the number 
of rhinovirus positive samples, but this was detected only in boys. The reasons for 
this sex-dependent difference are currently not known but previous data have 
suggested that sex might affect the susceptibility to both viral infections and atopic 
diseases. Other included viruses showed no association with atopy.  
In conclusion, the results from the present study demonstrate that early 
enterovirus infections are inversely associated with atopy in childhood and the results 
provide further support to the hygiene hypothesis. The pathogenesis of atopic 
diseases is a multifactorial process involving genetic predisposition and various 
environmental factors, and the results from this study suggest that enteroviruses 
represent one aspect of this pathogenetic entity. This study shows that enteroviruses 
are interesting viruses with respect to the development of atopy but further studies 
are still needed to clarify their possible causal relationship with atopy. 
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TIIVISTELMÄ 
Atooppisten sairauksien eli astman, allergisen nuhan ja atooppisen ihottuman 
esiintyvyyden nopea kasvu viime vuosikymmeninä on herättänyt kiinnostusta 
ympäristötekijöiden osuudesta näiden sairauksien synnyssä. Ns. hygieniahypoteesin 
mukaan elinympäristön mikrobialtistuksen muuttuminen ja lapsuusiän 
mikrobikontaktien väheneminen johtavat kehittyvän immuunijärjestelmän säätelyn 
häiriintymiseen ja lisääntyneeseen allergiariskiin. Atooppinen reaktiotapa kehittyy 
usein varhaislapsuudessa, mahdollisesti jo sikiöaikana. Täten varsinkin varhaiset 
mikrobi-infektiot saattavat olla erityisasemassa atooppisten sairauksien synnyssä. 
Enterovirukset ovat yleisiä lapsuusiän infektioiden aiheuttajia ja aiempi 
tutkimusnäyttö on antanut viitteitä enterovirusten ja atooppisten sairauksien välisestä 
yhteydestä.  
Tämän väitöskirjan tavoitteena oli tutkia varhaisten enterovirusinfektioiden 
yhteyttä atopiaan. Tutkimuksessa verrattiin enterovirusten esiintymistä 
prospektiivisesti kerätyissä veri- ja ulostenäytteissä atooppisilla tapauslapsilla ja ei-
atooppisilla verrokkilapsilla. Lisäksi tutkimuksessa selvitettiin äidin 
raskaudenaikaisen enterovirusinfektion yhteyttä lapsen myöhempään atooppisen 
sairauden riskiin.  
Varhaislapsuuden aikana sairastettujen eri enterovirustyyppien aiheuttamien 
infektioiden määrää selvitettiin tutkimalla neutraloivien vasta-aineiden esiintymistä 
12 eri enterovirustyyppiä kohtaan. Tutkimuksessa enterovirukset ryhmiteltiin 
echoviruksiin ja coxsackieviruksiin. Tutkimus osoitti, että atooppiset tapauslapset 
olivat sairastaneet merkittävästi vähemmän echovirusinfektioita ensimmäisen 
kahden elinvuoden aikana kuin ei-atooppiset verrokkilapset. Tutkimustulos tukee 
aiempia poikkileikkausasetelmasta saatuja tuloksia, joissa echovirusinfektioiden ja 
atopian välillä on todettu käänteinen yhteys. 
Äidin raskausaikana sairastaman enterovirusinfektion esiintyvyyttä selvitettiin 
mittaamalla enterovirusvasta-ainetasot alkuraskauden seeruminäytteestä ja 
synnytyksen yhteydessä otetusta napaverinäytteestä. Tutkimus osoitti, että 
raskausaikaiseen enterovirusinfektioon viittaavia vasta-ainetasojen nousuja oli 
vähemmän niillä äideillä, joiden lapsille kehittyi myöhemmin atooppinen sairaus. 
Muilla tutkituilla mikrobeilla (A-tyypin influenssavirus, Mycoplasma pneumoniae, 
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sytomegalovirus, Helicobacter pylori) ei todettu olevan yhteyttä lapsen atopiariskiin. 
Raskaudenaikaisen enterovirusinfektion yhteyttä atopiaan ei ole aiemmin tutkittu. 
Lisäksi tutkittiin enterovirusten esiintymistä ensimmäisen elinvuoden aikana 
kerätyissä ulostenäytteissä ja niiden yhteyttä lapsen atooppiseen herkistymiseen. 
Ulostenäytteistä tutkittiin rinoviruksia, jotka kuuluvat Enterovirus-sukuun, 
enteroviruksia, noroviruksia ja parechoviruksia. Tulokset osoittivat, että atooppisesti 
herkistyneillä lapsilla oli vähemmän rinoviruspositiivisia näytteitä mutta tämä tulos 
oli nähtävissä vain pojilla. Todetun sukupuolieron merkitys on toistaiseksi epäselvä, 
mutta aiemmat tutkimustulokset ovat viitanneet sukupuolten välisiin eroihin sekä 
virusinfektioiden että atooppisten sairauksien osalta. Muut tutkitut virukset eivät 
yhdistyneet lapsen atooppiseen herkistymiseen. 
Yhteenvetona voidaan todeta, että tutkimuksessa havaittiin varhaisten 
enterovirusinfektioiden olevan käänteisesti yhteydessä lapsen atopiaan ja 
tutkimustulokset tukevat siten osaltaan hygieniahypoteesia. Atooppisten sairauksien 
kehittyminen on kuitenkin monimutkainen tapahtuma, johon vaikuttavat sekä 
geneettinen alttius että erilaiset ympäristötekijät. Tutkimustulokset viittaavat siihen, 
että enterovirukset ovat osa tätä atopian syntyyn johtavaa kokonaisuutta. Tämä 
tutkimus osoitti enterovirusten olevan mielenkiintoinen virusryhmä atopian synnyssä 
mutta syy-seuraussuhteen varmistamiseksi tarvitaan vielä jatkotutkimuksia.  
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1 INTRODUCTION 
There has been a dramatic increase in the prevalence of atopic diseases over the 
recent decades (1,2) and this ‘allergy epidemic’ has also been observed in Finland 
(3,4). For instance, in Finland, the prevalence of asthma increased from 0.3% to 
3.5% between years 1966-2003 and the prevalence of allergic rhinoconjuctivitis 
increased from <0.1% to 9% by the year 2000 (4). This rapid increase suggests that 
environmental factors are important in this phenomenon. This is further supported 
by differences in the prevalence of atopic diseases in populations with genetic 
similarities but markedly different living environments (5-7). 
The ‘hygiene hypothesis’ was introduced in the year 1989. The original study 
showed that a child’s risk of allergic rhinoconjuctivitis was decreased in families with 
many older siblings (8). This and similar observations from other studies, led to the 
hypothesis stating that increased microbial contacts might protect from the 
development of atopy. The current concept of hygiene hypothesis suggests that 
recent changes in lifestyle in industrialized countries have led to reduced 
environmental microbial diversity and diminished infectious burden predisposing to 
the development of atopy (9).  
Enteroviruses (EVs) belong to the Picornaviridae virus family and they are 
common viruses worldwide. Several EV types affect humans, i.e. EV types from 
species A to D and rhinoviruses (RVs), and they can cause a wide spectrum of 
diseases. Cross-sectional study settings have suggested that EVs might be interesting 
viruses with regard to protection from atopy (7,10,11) but prospective studies are 
lacking. For RVs, RV-associated wheezing episodes have been shown to predispose 
to the development of asthma in childhood (12) but there are limited data about the 
role of RVs in other atopic diseases and IgE sensitization.  
The purpose of the present study was to evaluate the possible associations 
between EV infections and atopy in prospective study settings. The relation between 
cumulative exposure to different EV types during early childhood and atopy was 
assessed. In addition, the association between maternal EV infection during 
pregnancy and atopic disease in the offspring was analyzed. Further, the possible 
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role of repeated EV exposure in infancy was studied by detecting EVs (including 
RVs) from stools and analyzing the associations with atopic sensitization.  
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2 REVIEW OF THE LITERATURE 
2.1 Atopic diseases 
2.1.1 Definition 
The nomenclature applied in allergology has been defined and published by 
international allergy organizations in 2004 (13). In that report, allergy is defined as 
“a hypersensitivity reaction initiated by specific immunologic mechanisms” (13). The 
same report defines hypersensitivity as “objectively reproducible symptoms or signs 
initiated by exposure to a defined stimulus at a dose tolerated by normal persons” 
(13). Allergy can be further classified into antibody-mediated or cell-mediated allergy, 
according to the immunologic mechanisms behind the symptoms. In antibody-
mediated allergy, the antibodies belong typically to the immunoglobulin (Ig) E 
isotype, and these patients have IgE-mediated allergy, i.e. atopic allergy. 
The word “atopy” was introduced in 1923 and is derived from the Greek word 
atopia (unusualness, being out of the way) from a- (not, without) and topos (place) 
(14). Atopy is “a personal and/or familial tendency, usually in childhood or 
adolescence, to become sensitized and produce IgE antibodies in response to 
ordinary exposures to allergens, usually proteins. As a consequence, these persons 
can develop typical symptoms of asthma, rhinoconjuctivitis or eczema” (13). In 
other words, atopy describes a tendency to produce IgE antibodies against common 
environmental allergens, such as pollens, animal dandruff and foods, which often 
manifests as atopic diseases. Atopic diseases include atopic eczema (also called atopic 
dermatitis), allergic asthma and allergic rhinoconjunctivitis. As also included in the 
definition of atopy, atopic diseases begin typically in childhood.  
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2.1.2 IgE and atopic diseases 
In physiology, IgE-mediated immune reactions are thought to be central in host 
defense against parasites, such as helminths. One of the major pathologic roles of 
IgE involves immediate type 1 hypersensitivity reactions (15). In the sensitization 
phase of this IgE-mediated allergy, an antigen, i.e. an allergen, is presented by 
antigen-presenting cells to naïve T cells in the lymph nodes. In the presence of 
interleukin (IL)-4 and other T helper (Th)2 type cytokines, T cells are primed into 
effector Th2 cells, which stimulate the production of allergen-specific IgE antibodies 
in B cells. These IgE antibodies bind to high-affinity IgE receptor (FcεRI) expressed 
on the surface of mast cells and basophils. During an allergic reaction, contact with 
the specific allergen cross-links the receptor-bound IgE resulting in the 
degranulation of mast cells and basophils and secretion of active mediators such as 
histamine and tryptase. The release of these mediators leads e.g. to vasodilatation and 
contraction of bronchial smooth muscle, resulting in the clinical manifestations of 
an acute allergic reaction. 
The role of IgE in the pathogenesis of chronic atopic diseases is less clear and is 
likely to depend on the type of the disease. Atopic diseases are usually considered to 
include asthma, atopic eczema and allergic rhinoconjuctivitis (13). However, it has 
become increasingly evident that these diseases are not uniform but rather a 
heterogeneous group of illnesses presenting with various phenotypes. These 
phenotypes share similarities in clinical manifestations but have different etiologies 
and pathogenetic mechanisms. Accordingly, also the role of IgE in atopic diseases 
varies. For instance, allergic asthma is a common asthma phenotype especially in 
childhood and it is associated with IgE sensitization and Th2-type immune response 
(16). On the other hand, especially in adults, the significance of other types of asthma 
is more important and the role of IgE in their pathogenesis is less clear. For atopic 
eczema, most patients have elevated levels of serum total IgE and many have IgE-
mediated allergies such as hay fever and oral allergy syndrome (17). However, 
approximately 20% of patients with atopic eczema have normal IgE levels, a clinical 
phenotype sometimes referred as intrinsic atopic eczema (18). High total IgE has 
been shown to predict poor long-term outcome in atopic eczema (17) but the role 
of IgE in the pathogenesis of atopic eczema is unsolved. For instance, omalizumab, 
an anti-IgE antibody, is efficient in the treatment of severe allergic asthma but its 
efficacy in the treatment of atopic eczema is modest at best (19).  
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2.1.3 Epidemiology 
Atopic diseases are the most common non-communicable diseases in childhood in 
affluent countries. Numerous epidemiological studies confirm a substantial increase 
in the incidence of atopic diseases during the past decades and the term “allergy 
epidemic” has been applied (2-4,20-22). 
First reports of a sharply increasing incidence of childhood asthma were 
published in the 1960s (20) and the increase has continued, as demonstrated for 
instance by Haahtela et al for young men in Finland (3). In that study, the prevalence 
of asthma recorded at call-up examinations for military service increased from 0.08% 
in 1961 to 1.79% in 1989, and in the follow-up study in 2003, the prevalence was 
still increasing (4). A similar trend has also been observed for other atopic diseases. 
For example, in a British study the prevalence of eczema and hay fever in adolescents 
increased between 1974 and 1986 from 3% to 6% and from 12% to 23%, 
respectively (2). In Finland, the prevalence of atopic eczema in young men increased 
from the 1960s until the 1980s but has thereafter remained relatively constant (4). In 
the same study, the prevalence of allergic rhinoconjuctivitis remained <0.1% until 
the 1970s but increased thereafter being 9% in the year 2000 (4).  
There are geographical variations in the prevalence of atopic diseases. In the 
International Study of Asthma and Allergies in Childhood (ISAAC) published in 
1998, children aged 13-14 years worldwide answered a standardized questionnaire 
about symptoms of atopic diseases (23). Globally, there were 20-fold differences in 
the prevalence of asthmatic symptoms with the highest prevalence in the United 
Kingdom, New Zealand and Australia, and the lowest prevalence in Eastern Europe, 
Indonesia and China. For allergic rhinitis and atopic eczema there were no clear 
geographical trends as the centers with the highest prevalence were scattered around 
the world (23). The authors interpreted that this scattering might result e.g. from 
differences in diagnostic criteria or in the frequencies of risk factors, or from issues 
related to the validity of the questionnaires (23). 
A large-scale study on the time trends of atopic diseases worldwide was published 
in 2006 (22). Based on questionnaires performed 4-9 years apart, it reported that 
most centers showed an increase in the prevalence of childhood atopic diseases 
(Figures 2-4 in reference 22). Finland was included in the study, and results from 
children aged 13-14 years showed a modest increase in the prevalence of asthma and 
atopic eczema, with an increase from 13% to 19% and from 13% to 16%, 
respectively. The prevalence of allergic rhinoconjuctivitis was 15% and did not 
change during the follow-up (22). The prevalence of asthma and allergic 
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rhinoconjuctivitis in Finland was in line with most other northern and western 
European countries whereas the prevalence of atopic eczema was higher than in 
most European countries (22). Subsequently, systematic reviews aiming to assess 
global trends in the prevalence of atopic eczema and asthma have been published 
(24,25). The prevalence of asthma was still increasing in most countries, including 
many European countries (24). The prevalence of atopic eczema continued to 
increase for instance in the United Kingdom, Estonia and Lithuania but decreased 
or stayed stable in Sweden and Norway (25).  
A particular feature of atopic diseases is the marked variance in prevalence in 
populations with similar genetic backgrounds but living in adjacent countries with 
different environments. For example, the prevalence of hay fever among 
schoolchildren was 16 % in Finnish North Karelia and 1% in adjacent Russian 
Karelia (6). In the same way, atopic sensitization was found to be more common in 
Finland than in Russia (6,7). The same observation of more frequent aeroallergen 
sensitization and hay fever in westernized societies was reported previously in a study 
comparing children living in West Germany and East Germany (5). However, 5 years 
after the German unification, these disparities were diminishing, i.e. the prevalence 
of hay fever and atopic sensitization was increasing in children living in former East 
Germany (26). In contrast to Germany, the differences in the prevalence of atopic 
diseases and IgE sensitization between schoolchildren living in Finland and Russian 
Karelia have remained relatively constant, possibly reflecting the rather slow rate of 
urbanization in Russian Karelia (27).  
 
2.2 Enteroviruses 
Picornaviridae is a virus family comprised of small single-stranded ribonucleic acid 
(RNA) viruses. Currently the family consists of 35 genera containing 80 species (28). 
Picornaviruses can cause subclinical or symptomatic infections in both humans and 
animals. Enterovirus genus is one of the Picornaviridae genera and it comprises of 15 
species; 12 EV species and 3 RV species.  
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2.2.1 Enterovirus species A-D 
2.2.1.1 Classification and structure 
EVs belong to the Enterovirus genus of the Picornaviridae family. Traditionally EVs 
have been classified into four groups, namely group A coxsackieviruses (CV-As), 
group B coxsackieviruses (CV-Bs), echoviruses (Es) and polioviruses (PVs), 
according to their antigenic and biological properties (29). The molecular 
characterization of the viral genome has led to the present classification where EVs 
are classified according to their genetic similarities (30). Currently, the Enterovirus 
genus consists of 15 species, namely Enterovirus A-L and Rhinovirus A-C (28). Viruses 
affecting humans belong to species Enterovirus A-D and Rhinovirus A-C (Table 1).  
EVs have a simple structure with a protein capsid surrounding the single-stranded 
RNA genome. The capsid is a symmetrical icosahedral structure composed of 60 
identical capsomeres, each formed by four structural proteins; viral protein (VP)1, 
VP2, VP3 and VP4, with VP1-3 on the surface of the capsid and VP4 located inside 
the capsid (28,30). There are also non-structural proteins that take part in viral 
genome replication and virus-host cell interactions (31).  
 
2.2.1.2 Epidemiology and clinical disease 
EVs are among the most common human viruses worldwide, and they are 
transmitted via the orofecal or respiratory route. It has been estimated that every 
year 10-15 million symptomatic EV infections occur in the United States (32). The 
incidence of symptomatic EV infections is highest among children with 44% of 
infections occurring in infants under the age of one year (32). EV infections follow 
a seasonal pattern, which is more pronounced in temper climates where infections 
peak in summer and fall (33). In addition to this annual seasonality, individual EV 
types show different long-term circulation patterns and can occur in sporadic 
epidemics (34). 
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Table 1.  Enterovirus species and types affecting humans 
Species Types Number of types 
Enterovirus A CV-A2 to CV-A8, CV-A10, CV-A12, CV-A14, CV-A16, EV-
A71, EV-A76, EV-A89, EV-A90, EV-A91, EV-A114, EV-A119 
to EV-A121 
20 
Enterovirus B CV-B1 to CV-B6, CV-A9, E1 (incl. E8) to E7, E9 (incl. CV-
A23), E11 to E21, E24 to E27, E29 to E33, EV-B69, EV-B73 
to EV-B75, EV-B77 to EV-B88, EV-B93, EV-B97, EV-B98, 
EV-B100, EV-B101, EV-B106, EV-B107, EV-B111 
59 
Enterovirus C PV1 to PV3, CV-A1, CV-A11, CV-A13, CV-A17, CV-A19 to 
CV-A22, CV-A24, EV-C95, EV-C96, EV-C99, EV-C102, EV-
C104, EV-C105, EV-C109, EV-C113, EV-C116 to EV-C118 
23 
Enterovirus D EV-D68, EV-D70, EV-D94, EV-D111 4 
Rhinovirus A RV-A1, RV-A2, RV-A7 to RV-A13, RV-A15, RV-A16, RV-
A18 to RV-A25, RV-A28 to RV-A34, RV-A36, RV-A38 to RV-
A41, RV-A43, RV-A45, RV-A46, RV-A47, RV-A49, RV-A50, 
RV-A51, RV-A53 to RV-A68, RV-A71, RV-A73 to RV-A78, 
RV-A80, RV-A81, RV-A82, RV-A85, RV-A88, RV-A89, RV-
A90, RV-A94, RV-A96, RV-A100 to RV-A109 
80 
Rhinovirus B RV-B3 to RV-B6, RV-B14, RV-B17, RV-B26, RV-B27, RV-
B35, RV-B37, RV-B42, RV-B48, RV-B52, RV-B69, RV-B70, 
RV-B72, RV-B79, RV-B83, RV-B84, RV-B86, RV-B91 to RV-
B93, RV-B97, RV-B100 to RV-B106 
32 
Rhinovirus C RV-C1 to RV-C56 56 
CV, coxsackievirus; EV, enterovirus; E, echovirus, PV, poliovirus; RV, rhinovirus 
 
 
 
More than 100 EV types can infect humans causing a wide spectrum of clinical 
manifestations. Although most EV infections are asymptomatic or mild, EVs also 
cause upper respiratory infections, herpangina and hand-foot-mouth disease 
(HFMD), as well as more severe diseases, such as meningitis, encephalitis, flaccid 
paralysis and myocarditis (35). The severity of the infection depends on both the 
virus type and host-specific factors, for instance young age and male gender 
predispose to more severe disease (35). Certain species A EV types, especially EV-
A71, CV-A10 and CV-A16, are typical pathogens causing HFMD (36), and CV-Bs 
are significant pathogens in acute myocarditis and chronic dilated cardiomyopathy 
(37). EVs, especially CV-Bs, have also been shown to cause subclinical chronic 
pancreatitis and they have been linked to the development of type 1 diabetes (T1D) 
(38). 
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2.2.1.3 Laboratory diagnostics 
Laboratory methods applied to diagnose EV infections include virus isolation and 
culture, serology, such as enzyme immunoassay (EIA) and neutralization assay, and 
direct virus detection, such as reverse transcription polymerase chain reaction (RT-
PCR). Virus isolation and culture are used primarily in research work. Analysis of 
neutralizing antibodies (NABs) requires cell culture facilities and a virus isolate, and 
is thereby rarely used in clinical diagnostics. NAB levels can remain elevated for years 
after an infection, and thereby reflect the infection history of the individual. 
Measuring NABs also allows serotype-specific identification of EVs.  
Another serological method is the detection of IgM or IgG antibodies by EIA. 
Measuring of IgM antibodies can be applied to detect acute or recent infections. 
However, it may lead to false negative findings since EV infections do not always 
elicit clear IgM responses and/or these responses may not be detectable by the EV 
type used as an antigen in the assay (39). Detection of an increase in the IgG levels 
between paired sera can also be applied to diagnose acute EV infections. 
Nevertheless, the value of serological assays in clinical diagnostics is limited due to 
the high prevalence of EV antibodies in healthy background population and the 
cross-reactivity of antibodies between different EV types (39). Serological methods 
are also time consuming and often require paired sera making them impractical for 
the diagnosis of acute infections.  
Direct detection of virus RNA with molecular methods, especially RT-PCR, has 
largely replaced virus culture and serology in EV diagnostics in clinical virus 
laboratories. RT-PCR is a sensitive and specific method for the detection of EVs 
(40) and it can be used for several types of samples, typically cerebrospinal fluid, 
respiratory samples and stool. Most RT-PCR applied in EV diagnostics target the 
highly conserved 5’ untranslated region (UTR) and are suitable for the diagnosis of 
all EV types (39). Virus typing can be obtained by sequencing the viral genome or 
part of it, typically the regions coding for VP1, VP2 or VP4. 
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2.2.2 Rhinovirus species A-C 
2.2.2.1 Classification and structure 
RVs are single-stranded RNA viruses that belong to the Enterovirus genus of the 
Picornaviridae family. There are currently over 160 RV types identified capable of 
infecting humans and they are classified into three species: Rhinovirus A-C (Table 1). 
RVs have a symmetrical icosahedral protein capsid encasing the RNA genome. 
The capsid is composed of four structural proteins (VP1-VP4), while nonstructural 
viral proteins are involved in genome replication and assembly of new viruses (41). 
 
2.2.2.2 Epidemiology and clinical disease 
RVs are among the most common pathogens causing upper respiratory tract 
infections. For example, RVs were detected in 71% of nasopharyngeal aspirate 
samples collected from Finnish children with common cold-like illnesses (42). A 
large number of different RV strains circulate each year with the highest incidence 
of infections from September to November and from April to May (43). RV species 
A and C were shown to be the most common RVs in young children and they were 
also associated with more severe respiratory infections in this age group (44). RVs 
are transmitted primarily through the respiratory route. They cause typically 
common cold-like illnesses but can also cause a wide range of other diseases, such 
as acute otitis media, bronchiolitis and pneumonia, as well as exacerbations of 
chronic pulmonary diseases including asthma (45).  
 
2.2.2.3 Laboratory diagnostics  
Culturing RVs is more complicated than that of EVs, and RV-Cs do not grow on 
regular cell cultures. Therefore, virus culture is mainly used for research purposes. 
RVs lack an antigen common to all strains, which also makes serology impractical 
for clinical use. Hence, RT-PCR is nowadays the method of choice in the detection 
of RVs in clinical settings (41,45). Many of the commercial RT-PCR assays target the 
5’UTR region, a highly conserved genomic region among all RVs and EVs (41), but 
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RT-PCR tests able to differentiate between RVs and EVs have also been published 
(46). When specific information about the RV type or strain is needed, genotyping 
of the VP1 and/or VP4 region can be applied (41).  
 
2.2.3 Pathogenesis  
The primary replication site of EVs is the lymphoid tissue of small intestine and 
pharynx, whereas RV replication occurs typically in the nasal epithelium and 
nasopharynx. Viruses utilize a variety of cell surface receptors to enter the cell and 
the expression of these receptors in human cells contributes to the tissue-specific 
virulence of the virus. For example, E1, a prevalent EV among children, binds to 
α2β1 integrin, which is abundantly expressed on the cell surface of many cell types 
(47). On the other hand, EV-D68 shows respiratory tropism and it was found to 
bind to sialic acids containing cell surface receptors, which are extensively expressed 
on human airway tract epithelia (48). Upper respiratory epithelium also expresses 
intracellular adhesion molecule 1(ICAM-1), a cell surface receptor necessary for the 
cell entry of most RV-A and RV-B types (41). On the contrary, RV-Cs utilize a 
different receptor molecule, namely cadherin-related family member 3 (CDHR3) 
(49).  
After entering the target cell, viral genomic RNA is released and acts as a template 
for protein synthesis and the formation of new virions. Multiple EV-encoded 
proteins and host-dependent factors are involved in protein translation and virus 
replication (31). In EV infections, after replication in the primary replication site, e.g. 
small intestine, a viremia ensues seeding multiple organ systems, such as the central 
nervous system. The subsequent replication at these sites results in signs and 
symptoms of an EV infection (29). In RV infections, viremia is less common and 
might be associated with a more severe disease (50).  
The tissue tropism of EVs also depends on physical factors, such as 
environmental pH and temperature. For example, RVs were originally thought to 
replicate optimally at 33ºC with marked reduction of replication in temperatures of 
37-39ºC. Accordingly, RVs have been considered clinically relevant pathogens only 
in the upper respiratory tract where temperatures are below the inner body 
temperature. However, newer data have shown that some RVs are capable of 
replicating almost similarly at 33ºC and 37ºC, and the virus titres at 37ºC have been 
still adequate to initiate an infection (51).  
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Upon virus infection, the host immune system activates and EV-derived proteins 
and nucleic acids are recognized by host pattern recognition receptors, such as Toll-
like receptor (TLR) 7 and TLR8 (43). Activation of these receptors promotes gene 
expression of various mediators of inflammation, such as interferons (IFN) and 
chemokines that attract and activate immune cells at the site of infection. The initial 
activation of the host innate immune system augments pathogen-specific adaptive 
immune system, i.e. humoral and cell-mediated immunity. Viruses, including EVs, 
have been shown to induce a strong Th1-type immune reaction accompanied by 
IFN production (52).  
 
2.3 Hygiene hypothesis 
A rapid increase in the prevalence of atopic diseases over the past few decades 
implicates that environmental factors play an important role in the phenomenon. 
This is further supported by observations showing marked variations in the 
prevalence of atopic diseases in genetically similar groups living in different 
environments (5-7). The core of the ‘hygiene hypothesis’ lies in the idea that recent 
changes in lifestyle in affluent countries have led to the decreased burden of 
infectious diseases resulting in the increased prevalence of atopic diseases. The 
hygiene hypothesis was introduced by Strachan, who reported the risk of hay fever 
in childhood to be inversely associated with the number of older siblings (8). His 
hypothesis was that contact with siblings in early childhood predisposes the child to 
microbial infections, which in turn protects from atopic diseases. Since the initial 
introduction of the hygiene hypothesis, relation of atopy and different aspects of 
environmental exposures and microbial contacts have been studied abundantly 
(53,54). For instance, having older siblings has been shown to decrease neonatal gut 
colonization by Clostridium bacteria and to associate with a decreased risk of atopic 
eczema (55), and the amount of household dust and its’ endotoxin load have been 
observed to inversely associate with atopic sensitization and asthma (56). The 
concept of hygiene hypothesis has also been extended to autoimmune diseases, such 
as T1D (57) and multiple sclerosis (58).  
Recently, it has been suggested that the hygiene hypothesis should be expanded 
to include environmental microbiota in a broader sense. The proposed ‘biodiversity 
hypothesis’ connects the loss of global biodiversity with reduced human commensal 
microbiota and susceptibility to disease, including atopic diseases (59,60). In other 
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words, reduced contact with diverse environmental microbiota might hinder the 
development of robust host microbiota leading to immune dysregulation and 
increased risk of disease. For instance, IgE sensitized individuals have been shown 
to have lower environmental biodiversity in their immediate surroundings as well as 
lower bacterial diversity on their skin as compared to non-atopic individuals (61). 
 
2.3.1 Environmental factors  
2.3.1.1 Farming 
Numerous studies have shown that living in a farm is inversely associated with atopic 
sensitization, hay fever and asthma. Examples of this ‘farm effect’ include the 
findings that regular contact with farm animals and regular farm milk consumption 
are associated with protection from atopic diseases (62-64). In addition, the 
combination of living in a farm and having a large family markedly decreased the risk 
of atopy with the lowest risk being in children living in farms and having three or 
more siblings (65).  
The protective effect of the farm environment is probably mediated through 
various mechanisms, one of which might be increased microbial exposure. For 
instance, bacterial endotoxin levels in mattress dust were higher at homes of children 
living in farms, and endotoxin levels were inversely associated with atopic 
sensitization of the child (66). Another study showed that children living in farms 
were exposed to a wider range of microbial exposure than children in a non-farming 
environment were, and this microbial diversity was inversely related to asthma (67). 
It is possible that not only farming but also farming practices are important, as 
recently demonstrated in a study comparing the prevalence of asthma between 
Amish and Hutterite children (68). In that study, the Amish children had a 
significantly lower prevalence of asthma and atopic sensitization (68). As these two 
populations having similar genetic ancestries and lifestyles, with the exception of 
different farming traditions, the results were suggested to reflect the increased 
exposure to a diverse microbial environment associated with traditional farming 
practices in the Amish community as compared to the more industrialized farming 
practices among the Hutterites (68). The effect of urbanization on indoor microbiota 
has also been detected in a Finnish study, where the quantity of doormat debris and 
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the diversity of its bacterial communities decreased in accordance with the amount 
of built area around the home (69).  
 
2.3.1.2 Pet keeping 
Studies about the association between pet keeping and atopic diseases report 
conflicting results. The abundant data have yielded meta-analyses that have also 
ended up with different conclusions. A meta-analysis including cohort and case-
control studies reported a slightly increased risk of asthma in children exposed to 
dogs and a decreased risk of asthma in children exposed to cats (70). Another meta-
analysis including children participating in European birth cohort studies, found no 
association between contact with furry pets in early life and asthma or allergic rhinitis 
(71). For atopic eczema, an inverse association between exposure to dogs and the 
development of atopic eczema has been reported (72).  
Similarly to farm environment, the possible effect of pets on atopy might be 
mediated by their influence on the microbial environment within the home. In fact, 
the microbial composition of house dust was found to be richer and more diverse in 
homes with dogs than in households with no furry pets (73). Further, living with 
furry pets was shown to associate with changes in the gut microbiota in infancy (74).  
 
2.3.1.3 Family size 
One of the first researchers to report an inverse association between family size and 
atopy was Strachan in 1989 (8). He performed a large questionnaire-based cross-
sectional study and observed that the number of siblings, especially older siblings, 
was inversely related to hay fever at the age of 11 (8). Since that, an inverse 
association between family size and atopic disease or sensitization has been detected 
in many studies (65,75,76). The mechanisms behind this observation remain unclear 
but increased exposure to infections transmitted by siblings and maternal microbial 
pressure affecting the in utero environment have been suggested (76).  
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2.3.1.4 Day care attendance  
Studies about the effect of day care attendance on atopic diseases have shown 
conflicting results. Attendance in day care during early childhood has been found 
both to inversely associate with the development of asthma (77) and not to associate 
with childhood asthma (78). Similarly, day care attendance was observed to be 
inversely associated with atopic eczema in one study (79) but in another study, a 
positive association was reported (80). Controversies are present also in relation to 
IgE sensitization, as day care attendance has been reported both to inversely 
associate with IgE sensitization (81) and to increase the risk of food sensitization 
(78). The reasons for these discrepancies may reflect differences in parental atopy 
history, type and intensity of day care and child’s age at the beginning of day care. 
In fact, there are results suggesting that the child’s age at day care entry is 
especially important, as day care during the first six months of life was associated 
with protection from asthma whereas day care later in life was not (77). Similarly, 
atopic sensitization was more frequent among children who entered day care at the 
age of ≥ 12 months than in those entering at the age of 6-11 months (82). 
Early day care attendance might reflect the effects of early microbial stimulus but 
the data are inconclusive. For example, attendance in day care has been associated 
with an increased frequency of respiratory infections but adjusting for infections did 
not change the associations between day care attendance and atopic disease (78,81). 
 
2.3.2 Immunological aspects of the hygiene hypothesis 
2.3.2.1 Innate immunity 
Innate immunity system provides the first line of immune defense against pathogens. 
Innate immune responses are based on cellular expression of pattern recognition 
receptors, such as TLRs, RIG-I-like receptors and NOD-like receptors that 
recognize microbial components and activate immune reactions (83). In humans, 12 
TLRs have been identified to date, and TLR2, 3, 4, 7, 8 and 9 are known to be 
activated by viral components, including activation of TLR7 and TLR8 by single-
stranded RNA and TLR3 by double-stranded RNA (84). TLRs have also been linked 
to atopic diseases. Most data are derived from genetic variants of TLR2 and TLR4 
(85) but also mutations in the TLR7 and TLR8 loci have been shown to associate 
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with asthma and other atopic diseases (86). Upon activation, different TLRs activate 
different signaling cascades and the type of TLR activated might contribute to the 
development of atopic diseases, as reviewed for asthma (84).  
There are some data suggesting that the environment might modify the innate 
immune profile already in utero. TLR2 was upregulated in the cord blood of children 
born in Russian Karelia as compared to children born in Finland, which was 
suggested to reflect differences in the overall microbial load during pregnancy (87). 
In addition, maternal farming has been shown to associate with increased expression 
of TLR7 and TLR8 genes in cord blood cells (88) and maternal contact with farm 
animals during pregnancy was associated with increased expression of TLR2 and 
TLR4 in school-aged children (89). Furthermore, differences in cord blood TLR 
levels have been linked to atopy, as elevated levels of TLR5 and TLR9 in cord blood 
leucocytes were reported to associate with a reduced risk of atopic eczema (90).  
 
2.3.2.2 Th1 - Th2 paradigm 
Th cells are an integral part of the adaptive immune system. Classically, two types of 
activated Th cells have been characterized according to their cytokine production; 
Th1-type cells are characterized by the production of IFN-γ and Th2-type cells are 
characterized by the production of IL-4, IL-5 and IL-13. Typically, a Th1-type 
response is associated with autoimmune diseases like T1D, while allergic diseases are 
associated with a Th2-type response.  
This Th1/Th2 dichotomy, also characterized by mutual inhibition of Th1 and 
Th2 cells, has long been considered a cornerstone of adaptive immunity. 
Accordingly, atopic allergies have been seen to result from a Th1/Th2 imbalance 
favoring the Th2-type immune response. In other words, stimulation of the Th1-
type response, e.g. by a viral infection, might lead to decreased Th2 response and 
diminished risk of atopic diseases. However, as Th cell subtypes and functions have 
been shown to be far more diverse and plastic than originally postulated, the rigid 
Th1/Th2 dichotomy is proving to be an oversimplification (91). This might also 
explain why many studies have failed to show an inverse association between 
autoimmune disorders (i.e. alleged Th1-type diseases), such as T1D, and atopy (92).  
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2.3.2.3 Regulatory T cells 
The immune system needs to regulate itself in order to respond appropriately to 
harmful pathogens while tolerating harmless antigens. Regulatory T cells (Tregs) play 
a central role in this balance and maintain tolerance by numerous mechanisms, such 
as promoting tolerogenic dendritic cell (DC) phenotypes, suppressing Th cell 
activation as well as reducing the production of IgE and increasing the production 
of IgG4 in antigen-specific B cells (93). The classification of Tregs is not fully 
established but they can be classified into at least 5 subtypes based on the expression 
of transcription factor forkhead box P3 (FOXP3) (94). 
Tregs act in various ways, including secretion of soluble factors, such as IL-10 
and transforming growth factor (TGF)-β, and direct cell-to-cell contact. Abnormal 
Treg function has been described in atopic diseases even though the overall picture 
remains yet to be elucidated (93). For example, it has been shown in vitro that the 
presence of IL-10 reduced the effector function of allergen-specific DCs upon 
activation by the allergen, i.e. IL-10 inhibited Th2 proliferation and cytokine 
production (95). Tregs are also important players in the remodeling of immune 
tolerance during allergen immunotherapy, and allergen-induced FOXP3 expression 
has been shown to increase in peripheral blood mononuclear cells derived from 
children on immunotherapy (96). 
 
2.3.2.4 Epigenetics 
Epigenetic mechanisms control gene expression without altering DNA sequence. 
The increase in the prevalence of atopic diseases has been too rapid to be explained 
by changes in DNA sequence but epigenetic mechanisms, such as DNA methylation 
and histone modification, provide means by which environmental factors might 
modulate gene expression.  
Epigenetic regulation has also been studied in atopic diseases (97). For instance, 
pet keeping and exposure to tobacco smoke during childhood affected the degree of 
CD14 gene methylation, and CD14 is an important activator of innate immune 
responses (98). It is possible that epigenetic regulation begins already in utero. For 
example, altered DNA methylation at mitogen-activated protein (MAP) kinase 
signaling-associated genes, an important pathway for Th cell function, was observed 
in cord blood of children developing IgE-mediated food allergy as compared to non-
allergic children (99). 
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2.3.2.5 Microbiota  
The human microbiota is composed of microbial communities residing on or within 
the human body, for example skin, gut and airways. Alterations in the microbiota 
have been suggested to influence the susceptibility to atopic disease, particularly in 
early life when the immune system is maturating (54). Low diversity of gut 
microbiota in infancy was associated with subsequent atopic eczema (100). Similarly, 
bacterial diversity of intestinal microbiota at the age of 12 months was inversely 
associated with the risk of atopic sensitization and allergic rhinitis by the age of 6 
years (101). On the skin, commensal staphylococci were found to be less abundant 
during the first 6 months of life in children developing atopic eczema than in those 
with no eczema (102). In addition, a recent study showed that extracts from neonatal 
gut microbiota were able to modulate T cell function in vitro (103).  In that study, 
atopy-related gut microbiota promoted Th2-type immune response, i.e. increased the 
production of IL-4 and reduced the relative abundance of Tregs (103).  
Although traditionally thought to form during birth and breastfeeding, new 
observations suggest that the microbiota might start to form already in utero. Aagaard 
et al found a distinct, low-abundance but metabolically rich microbiota in placentas 
collected under sterile conditions (104). Their results also suggest that maternal 
infections might affect the placental microbiota, since maternal infections during the 
first half of pregnancy were associated with distinct shapes of placental microbiota 
(104). Further, it has been reported that placenta and amniotic fluid harbor similar 
microbiota that shares features with the newborn infant’s first intestinal discharge 
(meconium) (105). In addition, meconium microbiota has been found to differ from 
that at all other neonatal anatomic sites at birth (106). The shared features of 
microbiota in the placenta, amniotic fluid and neonatal gut led the authors to 
speculate that the early neonatal gastrointestinal microbiota might result from 
microbial transfer at the feto-placental interface (105,106).  
 
2.4 Enteroviruses and atopy  
Numerous microbes, including many viruses, have been studied in relation to atopic 
diseases and data are immense. Among the Enterovirus genus, the role of RV 
infections, especially RV-induced wheezing, in the development of asthma has been 
studied abundantly, whereas the role of species A-D EVs is less studied. The next 
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chapters provide an overview of the current data on EVs and atopy concentrating 
on EV species A-D and RVs.  
 
2.4.1 Enterovirus species A-D 
Gastrointestinal tract is important in the induction of tolerance and it has been 
suggested that gastrointestinal pathogens might be especially important with regard 
to atopy. In adults, seropositivity against hepatitis A virus (HAV) was observed to 
be inversely associated with atopy (107). Subsequent studies reported the risk of 
atopy to reduce with a gradient of exposure to HAV, Helicobacter pylori (H. pylori) and 
Toxoplasma gondii (T. gondii) (108,109), whereas another study observed no association 
between seropositivity to HAV, H. pylori or T. gondii and atopy (110). Similarly, 
gastrointerstinal noro- and rotavirus infections were not associated with protection 
from atopy in a prospective study including young children (111). In addition, 
seropositivity to intestinal bacterial pathogens causing typically acute infections 
(Clostridium difficile, Campylobacter jejuni, Yersinia enterocolitica) was associated with a 
higher prevalence of atopy (109). Altogether, it seems that some gastrointestinal 
pathogens might be inversely associated with atopy but the data are inconclusive.  
Consequently, also EVs might be interesting microbes with regard to the 
development of atopy; EVs can be transmitted orofecally and gastrointestinal tract 
is one of the primary replication sites of EVs. Seiskari et al observed in a cross-
sectional study setting that EV seropositivity at school age was inversely associated 
with IgE sensitization in Russian Karelia but not in Finland (7). They speculated that 
the difference between the countries might be explained by the assumption that 
Russian children are infected at a younger age, or that EVs are transmitted through 
different routes, for instance respiratory transmission predominating in Finland (7). 
They also found EV types to differ in their relation with IgE sensitization; CV-Bs 
were not associated with atopy, whereas certain other EV types, especially E11, were 
(10). However, E30 was associated with an increased risk of IgE sensitization, and 
the authors discuss that this might result from E30 infecting older children than 
other Es (10). In another study, the prevalence of E30 IgG antibodies was found to 
be inversely associated with total IgE levels and severe childhood asthma 
exacerbations (11) but the children included were younger than in the study by 
Seiskari et al. 
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In addition to orofecal transmission, EVs can transmit through the respiratory 
route and EVs are commonly isolated from nasal samples in children with severe 
wheezing illness; EVs were detected in 12 - 20% of nasopharyngeal aspirates taken 
from children hospitalized for acute wheezing (112,113).  Thereby, EVs appear to 
be one of the major pathogens causing acute wheezing in children but data about 
the relation between EV-induced wheezing and atopic disease are inconclusive. 
Regarding IgE sensitization, EV-induced wheezing requiring hospitalization was 
found not to associate with IgE sensitization in children, in contrast to RV-induced 
wheezing (114). For asthma, EV-induced wheezing was not associated with the 
development of asthma (112) or impaired lung function (115). On the contrary, in a 
large register-based study children with laboratory-confirmed symptomatic EV 
infections had a higher risk of asthma (116). In that study, most children had 
herpangina or hand-foot-mouth disease (HFMD) but also children with more severe 
forms of EV infection, such as meningitis, were included (116). Furthermore, 
another study from the same database concentrating only on EV-induced 
herpangina and HFMD showed that children with HFMD had a decreased risk of 
asthma, whereas children with herpangina had an increased risk of allergic rhinitis 
and atopic eczema (117). The authors speculated that HFMD, generally causing 
more severe symptoms than herpangina, might induce a more intense inflammatory 
cytokine production and thus decrease the risk of atopic disease (117). 
In summary, both gastrointestinal and respiratory EVs are frequent pathogens in 
childhood but data about the associations between EVs and the development of 
atopic disease or sensitization are inconclusive and there might be differences related 
e.g. to EV type and the route of infection. 
 
2.4.2 Rhinoviruses  
RVs and respiratory syncytial viruses (RSVs) predominate as pathogens in childhood 
wheezing episodes (118). Therefore, research about a possible relation between RVs 
and atopic disease has focused mostly on asthma. Both RV-induced and RSV-
induced wheezing have been linked to the subsequent development of asthma with 
RV showing an especially strong correlation in some studies (119). For example, 47% 
of children who had RV-induced wheezing illness during the first year of life had 
asthma at the age of 6 years in comparison with 24% of children with non-RV 
wheezing illness (119). Accordingly, in a recent meta-analysis RV-induced wheezing 
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during the first 3 years of life was found to associate with subsequent development 
of wheezing/asthma (12). As also discussed in the meta-analysis, most data about 
the relation of RV-induced wheezing and asthma are derived from cohorts known 
to be at high risk for developing asthma, i.e. children with atopic background or 
children with severe wheezing requiring hospitalization (12).  
However, it is possible that asymptomatic and symptomatic RV infections differ 
in their relation with asthma. Asymptomatic RV positivity in nasal samples during 
the first year of life was not associated with subsequent development of asthma, 
whereas RV episodes associated with wheezing were (119). Accordingly, in another 
study, the presence of RVs in nose and throat swabs collected regardless of 
symptoms was not associated with wheezing at the age of 4 years but wheezing RV-
episodes during the first year of life increased the risk of having wheezing at the age 
of 4 years (120). 
Genetic factors contribute extensively to the development of asthma and there is 
data linking this genetic susceptibility and RV infections (49,121). CDHR 3 is a 
transmembrane protein expressed on the airway epithelium and polymorphism of 
the CDHR3 gene locus has been identified important in susceptibility for severe 
childhood asthma (121). Interestingly, CDHR3 also mediates RV-C binding and 
replication (49). These findings suggest that RV-C infections could contribute to the 
development of childhood asthma. 
Several studies have shown that concomitant IgE sensitization further increases 
the risk of asthma in children with RV-induced wheezing (118,119). The results from 
a study aiming to define the temporal relationship between RV-induced wheezing 
and aeroallergen sensitization suggested that atopic sensitization preceded RV 
wheezing (122). In that study, an opposite relation was not true, i.e. RV-induced 
wheezing was not associated with subsequent aeroallergen sensitization (122).  
To conclude, RV-induced wheezing has been shown to be a risk factor for the 
development of asthma but data about the association between non-wheezing RV 
exposure and subsequent IgE sensitization or atopic disease are scarce. 
 
2.5 Prenatal factors and atopy in the offspring 
A number of phenotypic differences are present already at birth between children 
who develop atopic diseases and those who do not. For instance, reduced suppressor 
functions of Tregs and increased TLR-mediated innate immune responses were 
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observed in cord blood of newborns developing allergies in later life (123,124). As 
these differences were present already in newborns, it has been suggested that the 
factors influencing the risk of atopy might begin to act already in utero (125). 
 
2.5.1 Maternal environment 
A wide range of environmental exposures during pregnancy has been associated with 
atopy in the offspring. Among others, maternal smoking has been shown to associate 
with asthma (126), and maternal adverse life events increased the likelihood of 
asthma and eczema in the offspring (127). On the other hand, maternal exposure to 
farm environment has been shown to reduce the risk of atopy (89,90,128). In cross-
sectional studies, maternal contact with farm animals during pregnancy was inversely 
associated with IgE sensitization (89) and atopic disease (128) at school age. Later, 
in a prospective birth cohort, maternal contact with farm animals during pregnancy 
was inversely associated with atopic eczema in the offspring (90).  
 
2.5.2 Maternal infections 
In studies relying on questionnaires or medical records in determining infections, 
maternal febrile infections during pregnancy have been reported to associate with 
childhood eczema (129,130), rhinitis (129) and asthma (131-133) but this association 
has not been seen in all studies (134). Some studies also suggest that timing of the 
maternal infection might affect the risk, but the results are inconclusive, as both first 
trimester (129-131,133) and third trimester (132) have been suggested to be 
especially important.  
Data based on laboratory-confirmed gestational infections are less abundant. For 
bacteria, a Finnish study reported that adolescents born to mothers with an 
intrauterine growth of bacteria at the time of cesarean section were at an increased 
risk of asthma but not of atopic sensitization (135). For helminth infections, a 
Ugandan study observed maternal hookworm infection to be inversely associated 
with eczema in the offspring (136). They also found maternal asymptomatic malaria 
infection to have an inverse association with childhood eczema (136). In contrast, a 
study by Cooper et al observed no association between gestational hookworm 
infection and childhood atopic disease in rural Ecuador (137). However, they did 
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observe an inverse association between maternal helminth infections and inhalation 
allergen sensitization (137). With respect to viruses, there is an Australian study 
reporting more asthma and eczema in one-year-old children born to mothers with 
laboratory-confirmed upper respiratory tract viral infections during pregnancy as 
compared to children whose mothers had common cold symptoms without 
laboratory-confirmed viral infection (138). However, the study did not include a 
control group of mothers without respiratory infections, which might reduce the 
generalizability of the results. Combining the existing data, a meta-analysis concluded 
that maternal infections are positively associated with both asthma and eczema in 
the offspring (139). 
In summary, most data about the relation of maternal infections during 
pregnancy and atopic disease in the offspring are based on questionnaires and 
medical records. There are observations that gestational febrile infections might 
increase the risk of atopic disease, perhaps especially asthma, in the offspring. 
However, microbiological identification of the pathogen has been infrequent with 
only one previous study concentrating on virus infections.  
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3 AIMS OF THE STUDY 
The principal aim of this thesis study was to evaluate the association between EV 
infections in early life and atopy. The detailed aims were: 
1. To evaluate the association between EV infections during the first two years 
of life and atopic disease. 
2. To study the association between gestational EV infections and atopic 
disease in the offspring. 
3. To investigate the association between EVs, including RVs, detected in stool 
samples during the first year of life and IgE sensitization. 
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4 SUBJECTS AND METHODS 
4.1 Subjects 
4.1.1 DIPP study (Reports I and II) 
The Type 1 Diabetes Prediction and Prevention (DIPP) study is an ongoing 
prospective birth cohort study initiated in Finland in 1994 (140). In the DIPP study, 
children at moderate or high human leukocyte (HLA) conferred genetic risk for T1D 
are followed from birth until the onset of T1D or the age of 15 years. After informed 
parental consent, cord blood of infants born in the University Hospitals of Oulu, 
Tampere or Turku is screened for T1D-associated HLA-DQB1 alleles: DQB1*02, 
*0301, *0302 and *0602/3 (141). Infants carrying the high-risk genotype 
(DQB1*02/*0302) or the moderate-risk genotype (DQB1*0302/x, with x ≠ 
DQB1*02, *0301 or *0602) are invited to enter the study follow-up. During the 
follow-up, study subjects visit the study clinic and biological samples are collected 
every 3-6 months until the age of 2 years and thereafter every 6-12 months. During 
the follow-up children are screened for the presence of T1D-associated islet cell 
antibodies and, if applicable, for other T1D-related autoantibodies.  
 
4.1.2 Diabimmune study (Report III)  
The Diabimmune study is an international multicenter study that was carried out in 
three countries during the years 2008-2014. It included a birth cohort arm where 
T1D-related HLA-DR-DQ alleles were analyzed after informed parental consent 
from cord blood of infants born in Estonia, Finland and Russian Karelia. Children 
with high (DR3-DQ2/DR4-DQ8), moderate (DR4-DQ8/x, x=non-protective 
allele, not DR3-DQ2) or slightly increased (DR3-DQ2/y, y=non-protective allele, 
not DR4-DQ8) genetic risk for T1D were invited to enter the follow-up study lasting 
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for 3 years. Serum samples were drawn at 3, 6, 12, 18, 24 and 36 months and the 
families collected monthly stool samples. 
4.1.3 Subjects in Report I  
Report I was a nested case-control study within the DIPP study. For this study, the 
DIPP database was screened for children born in the Tampere University Hospital 
between 1.1.1998 - 31.12.2003 for a physicians’ diagnosis of asthma, atopic eczema 
or allergic rhinitis. Children with missing serum samples during the first 2 years of 
follow-up, discontinuing the follow-up before the age of 5 years and children with 
T1D-associated autoantibodies or T1D were excluded. As a result, 183 eligible 
children were identified. The serum samples drawn from the children at the age of 5 
years were screened for IgE antibodies against an aeroallergen mixture. Altogether 
71 children were IgE positive and they comprised the case group. Next, 142 non-
atopic control children, i.e. having neither a diagnosis of an atopic disease nor IgE 
sensitization at the age of 5 years, were selected. These control children were 
matched for age (median age difference 9 days, range 0-64 days), sex and HLA-
DQB1 genotype. Demographics of the study population are presented in Table 2 in 
chapter 5.1.  
 
4.1.4 Subjects in Report II 
Report II was a nested case-control study within the DIPP study. In addition to the 
DIPP samples, serum samples drawn from the mothers of the participating DIPP 
children were analyzed. Maternal serum samples were drawn at the end of the first 
trimester of pregnancy as part of the national screening protocol of infectious 
diseases in prenatal clinics. In Report II, the DIPP database was searched for 
children fulfilling the following case child criteria: Diagnosis of asthma, atopic 
eczema and/or allergic rhinitis recorded in the DIPP database and a positive serum 
IgE level against an aeroallergen mixture at the age of 5 years. Children with T1D or 
T1D-associated autoantibodies were excluded. Only children with maternal first 
trimester serum samples and cord blood samples were included. Altogether, 202 
children fulfilling these criteria were identified. These case children were born 
between June 1996 and September 2004 in the cities of Tampere (n=91) and Oulu 
(n=111).  
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Next, 1-2 non-atopic control children were selected for each case child (n=333). 
Case and control children were matched for sex, T1D-related HLA-DQB1 alleles, 
place of birth and time of birth (± 3 months). The median age difference between 
cases and controls was 43 days (range 0-91 days). The demographics of the study 
population are presented in Table 4 in chapter 5.2.  
 
4.1.5 Subjects in Report III  
Report III was a nested case-control study within the birth cohort arm of the 
Diabimmune study. The study cohort was selected among the 1139 children born in 
Finland (Espoo) and Estonia (Tartu) and carrying T1D-associated HLA-DR-DQ 
genotypes. Altogether 717 of these 1139 children participated in the Diabimmune 
birth cohort study and 563 continued in the study until the age of 3 years. Data about 
the IgE results from these 563 children were drawn from the Diabimmune database. 
Altogether, 244 children with at least one allergen-specific IgE level ≥ 0.35 kilounit 
per liter (kU/L) at the age of 18 and/or 36 months were identified.  These 244 
children comprised the case group. Then 244 non-sensitized, i.e. all specific IgE 
values < 0.35 kU/L at 6, 18 and 36 months, control children were selected. The 
control children were matched for the country of birth but otherwise they were 
selected randomly.  
There were 246 boys, including 140 (57%) cases and 106 (43%) controls, and 242 
girls, including 104 cases (43%) and 138 controls (57%). T1D-related HLA types 
were divided as follows: 25 (10%) cases and 20 (8%) controls had DR3-DQ2/DR4-
DQ8 genotype, 98 (40%) cases and 110 (45%) controls had DR4-DQ8/x (x=not 
DR3-DQ2 or a haplotype associated with protection against T1D) genotype and 121 
(50%) cases and 114 (47%) controls had DR3-DQ2/y (y=not DR4-DQ8 or a 
haplotype associated with protection against T1D) genotype. Case and control 
children were born between September 2008 and May 2010. Out of the 488 children 
included, 304 (62%) were born in Finland and 184 (38%) in Estonia. The 
demographics of the study population are presented for the whole cohort (Table 5) 
and after stratification by sex (Table 6) in chapter 5.3. 
Case children were further categorized according to their IgE sensitization 
profiles. Based on their age at the time of sensitization, case children were divided 
into two groups: “early sensitized” (n=57) and “late sensitized” (n=162) (IgE 
analyses at 6 months were missing from 25 children). Early sensitized children had 
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at least one specific IgE value ≥ 0.35 kU/L already at 6 months of age, and late 
sensitized children were IgE negative at 6 months but turned IgE positive later 
during the follow-up. In addition, case children were classified according to allergens; 
children sensitized against at least one aeroallergen (cat, dog, dust mite, birch, 
timothy) comprised the group “aeroallergen sensitized” (n=104) and children 
sensitized against at least one food (egg, milk, wheat, peanut) comprised to group 
“dietary sensitized” (n=214). When applicable, children could belong to both of 
these groups.  
 
4.2 Methods 
4.2.1 Neutralizing virus antibody assay (Report I) 
Serum samples taken at the age of 1 and 2 years were analyzed with a standard plaque 
reduction neutralization assay as described earlier (142). In the plaque neutralization 
assay, EV antibodies in the serum prevent the virus from infecting cells in vitro and 
this is detected by a reduction in cell death in cell culture. The 2-year samples were 
analyzed for the presence of NABs against 12 EV types: CV-B1, CV-B2, CV-B3, 
CV-B6, CV-A9, E3, E5, E9, E11, E21, E26, E30, 1-year samples were analyzed for 
E3, E5, E9, E11 and E30. Both American Type Culture Collection (ATCC) 
prototype virus strains (CV-B2, CV-B6, E9, E11, E30) and wild-type EV isolates 
from Finland (CV-B1, CV-B3, CV-A9, E3, E5, E21, E26) were used. A fourfold 
dilution of serum was applied and the serum was considered antibody positive when 
it reduced the number of virus-induced plaques by 80% or more. The analyses were 
carried out blind to the case-control status of the child.  
 
4.2.2 EIA virus antibody assay (Report II) 
In this study, the presence of IgG class antibodies against EV, influenza virus A 
(IAV), cytomegalovirus (CMV), H.pylori and M. pneumoniae was analyzed from cord 
blood and/or maternal first trimester serum samples. Antibodies were measured by 
EIA, except CMV antibodies, which were measured either by EIA or by 
chemiluminescent immunoassay (CLIA) due to changes in laboratory equipment 
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during the study period. EV, IAV and M. pneumoniae antibodies were analyzed from 
maternal first trimester samples and cord blood, H. pylori antibodies from cord blood 
and CMV antibodies from first trimester sample (n=146) or cord blood (n=381) 
according to availability. Case-control pairs as well as related first trimester and cord 
blood samples were analyzed parallel in the same test run. The samples were analyzed 
blind to clinical information. 
Following the manufacturer’s instructions, acute gestational M. pneumoniae 
infection was defined as a 1.6-fold or higher rise in antibody levels between first 
trimester serum sample and cord blood. For cohesion, the same criteria were applied 
for EV and IAV when detecting acute infections during pregnancy. The prevalence 
of gestational H. pylori and CMV infections in the Finnish population was estimated 
low and thereby the presence of H. pylori and CMV antibodies was analyzed only 
from a single serum sample. These microbes cause chronic or latent infections, 
which can be detected using a single sample.  
For EV, a synthetic peptide antigen KEVPALTAVETGAT-C was applied. This 
antigen is derived from the immunodominant region (VP1) of the EV virus capsid 
and it is known to detect several EVs (143,144). For IAV, IAV strain Beijing 
(BA1231VS, Virion Serion, Germany) was employed (145). Commercial kits were 
used for H. pylori (Enzygnost® Anti-Helicobacter pylori, Siemens, Germany) and M. 
pneumoniae (Mycoplasma pneumoniae, Labsystems Diagnostics Ltd, Finland) 
according to the manufacturers’ instructions. CMV antibodies were analyzed with 
Enzygnost® Anti-CMV EIA kit (Siemens, Germany) or with LIAISON® CMV IgG 
II CLIA kit (DiaSorin S.p.A, Italy) according to the manufacturer’s instructions.  
 
4.2.3 Detection of viruses by RT-PCR (Report III)  
The presence of RV, EV, norovirus (NoV) and parechovirus (HPeV) RNA in stool 
samples was analyzed by real-time reverse transcription quantitative polymerase 
chain reaction (RT-qPCR). Stool samples were collected monthly during the first 
year of life. Viral RNA was extracted from 10% stool suspension with Qiagen Viral 
RNA kit according to manufacturer’s protocol (Qiagen, Germany). Viral RNA was 
reverse-transcribed and amplified using the QuantiTect Probe kit (Qiagen, 
Germany). RT-qPCR was performed according to the manufacturer’s instructions 
with QuantiTect Probe kit using TaqMan® (Thermo Fisher Scientific, USA) 
chemistry labelled primers and probes. For RV, forward primer 5’-CYA* GCC 
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T*GC GTG GC -3’ (A* and T* locked nucleic acid primer by Exiqon, Denmark); 
reverse primer GAA ACA CGG ACA CCC AAA GTA and probe VIC-TCC TCC 
GGC CCC TGA ATG YGG C –TAMRA were applied, as described previously (46). 
For EV, forward primer: CGG CCC CTG AAT GCG GCT AA, reverse primer: 
GAA ACA CGG ACA CCC AAA GTA, probe 1: FAM-TCT GTG GCG GAA 
CCG ACT A-TAMRA, probe 2: FAM-TCT GCA GCG GAA CCG ACT A-
TAMRA were used (146). NoV and HPeV were detected with primers and probes 
as described (147). Every sample was analyzed in three parallel runs and the sample 
was interpreted positive if at least one of the parallel runs positive. The samples were 
analyzed blind to the case-control status of the child.  
 
4.2.4 Measurement of IgE antibodies  
In Reports I and II, IgE class antibodies against a mixture of aeroallergens 
(Phadiatop®, Phadia AB, Sweden) were measured by ImmunoCAP® enzyme 
immunoassay (Phadia AB, Sweden) from serum samples taken at 5 years of age. In 
Report III, specific IgE antibodies against cat, dust mite, birch, timothy, egg, milk 
and wheat were analyzed from serum samples taken at 6, 18 and 36 months, 
antibodies against peanut from samples taken at 18 and 36 months and antibodies 
against dog from 36-month sample by ImmunoCAP® (Phadia AB, Sweden). 
Analyses were carried out blind to clinical information and values ≥ 0.35 kU/L were 
considered positive. 
 
4.2.5 HLA typing 
In Reports I and II, T1D-associated HLA-DQB1 alleles were determined from cord 
blood as previously described (141). In Report III, HLA-DQ-DR analyses were 
performed as described (148).  
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4.2.6 Statistical methods 
In Report I, the association between EV seropositivity and atopic outcome was 
determined by conditional logistic regression analysis. The number of seropositivity 
against different EV types was calculated and used to estimate how much each 
seropositivity affects the child’s risk of having an atopic outcome. The results are 
presented as odds ratio (OR) and 95% confidence interval (CI) for the atopic 
outcome.  
In Report II, conditional logistic regression analysis was applied to determine the 
association between an acute infection during pregnancy (EV, IAV, M. pneumoniae) 
or seropositivity (CMV, H.pylori) and the atopic outcome. The results are expressed 
as OR and 95% CI for the atopic outcome.  
In the unmatched study population in Report III, logistic regression analysis was 
used to estimate ORs and 95% CIs for IgE sensitization. Each stool sample positive 
for viral RNA was included in the analyses as an independent positive value. 
Association between the number of virus-positive samples and the atopic outcome 
was evaluated by calculating the number of positive stool samples in each child 
during the 12-month follow-up (6-month follow-up in case categories “early 
sensitized” and “late sensitized”, see chapter 4.1.5.) and estimating how much each 
virus-positive sample affects the child’s risk to become IgE sensitized.  
Data about possible confounding factors are presented in Table 2 (Report I) and 
Table 4 (Report II). In Reports I and II, the possible confounding effects of sex, age 
and T1D-related HLA-DQB1 were controlled by matching on study inclusion. For 
other possible confounders, the effect of each factor on the study outcome was 
estimated by logistic regression analysis (univariate analysis). When a statistically 
significant association was observed, logistic regression analysis was used to adjust 
for this confounder. In Report I, none of the possible confounding factors was 
statistically significantly associated with atopic outcome. In Report II, furry animals 
at home and having older siblings were associated with atopic outcome and the 
results were adjusted for these confounders. Possible confounding factors in Report 
III are presented in Tables 5 and 6, and the possible effect of each factor on the 
study outcome was estimated by logistic regression analysis (univariate analysis). 
Prevalence of paternal atopy differed statistically significantly in the whole cohort 
and in girls and logistic regression analysis was applied to adjust for this confounder. 
In Report II, the Bonferroni correction was applied to counteract the problem of 
multiple comparisons. As the associations between gestational infections and atopic 
outcome were determined for three microbes (EV, IAV, M. pneumoniae), Bonferroni 
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correction by 3 was used.  For seropositivity analyses (H. pylori and CMV), 
Bonferroni correction by 2 was applied. The corrected thresholds for statistical 
significance were p < 0.017 and p < 0.025, respectively. In Report III, four different 
viruses were analyzed and after applying Bonferroni correction, p < 0.013 was 
regarded as statistically significant. Unadjusted p values are presented in the text.  
Analyses were performed using STATA 8.2. (Statacorp, USA) (Report I) and R 
version 3.3.3 (2017-03-06, The R Foundation for Statistical Computing, 
https://www.R-project.org) (Reports II and III).  
 
4.2.7 Ethical aspects 
The DIPP study protocol has been approved by the Ethical Committees of the 
participating University Hospitals of Oulu, Tampere and Turku. The Diabimmune 
study has been approved by the local Ethics Committees of the participating 
hospitals. The Finnish Maternity Cohort Steering Group at the National Institute for 
Health and Welfare (THL) approved the use of maternal first trimester serum 
samples in Report II. Written informed consent was obtained from parents of 
participating children.  
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5 RESULTS 
5.1 Neutralizing enterovirus antibodies and atopic disease 
(Report I) 
In Report I, the association between NABs against different EV types and the atopic 
outcome was investigated. The study comprised of 71 atopic case children and 142 
non-atopic control children. The demographics of the study population and their 
associations with the study outcome are presented in Table 2. NABs were measured 
against 12 different EV types from the serum samples drawn at the age of 2 years.  
EV infections were common in early life, as 61 (86%) case children and 119 (84%) 
control children had NABs against at least one EV type. Control children were 
seropositive against a higher number of different EV types than case children were 
and this accumulation of EV seropositivity was associated with protection from the 
atopic outcome (OR: 0.73; 95% CI: 0.56-0.96; p=0.025).  
Based on previously commonly used classification, CVs and Es were analyzed as 
separate groups. The number of children seropositive against at least one E or CV 
type did not differ between case and control children (75% vs 78% and 35% vs 32%, 
respectively). However, control children had NABs against a higher number of Es, 
which was inversely associated with the atopic outcome (OR: 0.63; 95% CI: 0.46-
0.88; p=0.006) (Figure 1). This association was not detected with CVs (OR: 1.06; 
95% CI: 0.67-1.66; p=0.82). None of the individual EV types showed statistically 
significant associations with atopy. For Es, the results showed a similar trend when 
children with asthma (n=29) and atopic eczema/allergic rhinitis (n=42) were 
analyzed separately (OR: 0.64; 95% CI: 0.39-1.04; p=0.069 and OR: 0.63; 95% CI: 
0.40-0.98; p=0.039, respectively), even though in asthmatic children the result was 
not statistically significant.  
In addition, NABs against E3, E6, E9, E11 and E30 were measured from serum 
samples drawn at the age of 1 year. The seroprevalence of these Es at the age of 1 
year and 2 years is shown in Figure 2. At this early age, 98 (69%) control children 
and 39 (55%) case children were seropositive against one or more E type, and this 
was inversely associated with atopic outcome (OR: 0.52; 95% CI: 0.28-0.96; 
p=0.038).  
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Table 2.  Demographic characteristics of the study population (Report I).  
 
Case 
n=71 (%) 
Control 
n=142 (%) 
 
OR (95% CI) 
 
p value 
Gender (male) § 43 (61) 86 (61)   
HLA-DQB1 genotype §     
     DQB1 *02/*0302 10 (14) 20 (14)   
     DQB1 *0302/x ¤ 61 (86) 122 (86)   
Atopic disease     
     Asthma 29 (41)    
     Atopic eczema 37 (52)    
     Allergic rhinitis 5 (7)    
Older siblings (yes) 35 (51) 85 (61) 0.64 (0.36-1.15) 0.14 
Smoking during pregnancy (yes) 5 (8) 9 (7) 1.06 (0.34-3.31) 0.92 
Indoor pet at home (yes) 18 (26) 39 (28) 0.91 (0.47-1.75) 0.78 
Maternal higher education # 39 (57) 64 (46) 1.45 (0.81-2.58) 0.21 
Paternal higher education # 30 (45) 53 (41) 1.11 (0.62-1.96) 0.73 
Entry into daycare † ¶  27 (15) 25 (16) 0.99 (0.96-1.01) 0.41 
OR, odds ratio; CI, confidence interval; §, case and control children were matched for sex and HLA-
DQB1 genotype; ¤, x refers to other alleles that *02, *0301 or *0602; #, higher secondary or tertiary 
education; †, child’s age in months; ¶, values are means (standard deviation in parenthesis). 
Associations with the atopic outcome (diagnosis of asthma, atopic eczema and/or allergic rhinitis and 
aeroallergen IgE positivity) are presented as OR and 95% CI. 
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Figure 1.  The percentage of children having neutralizing antibodies against 1-5 different echovirus 
types at the age of 12 and 24 months (Report I). 
 
 
 
 
Figure 2.  The percentage of children having neutralizing antibodies against echovirus 3 (E3), 
echovirus 5 (E5), echovirus 9 (E9), echovirus 11 (E11) and echovirus 30 (E30) at the age 
of 1 year and 2 years (Report I). 
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5.2 Gestational enterovirus infection and atopic disease in the 
offspring (Report II) 
Report II addressed the possible associations between gestational infections and 
atopic disease in the offspring. An increase in IgG levels against EV, IAV or M. 
pneumoniae during pregnancy was interpreted as an acute infection during pregnancy. 
In addition, seropositivity against CMV and H. pylori was analyzed from either cord 
blood or first trimester serum sample taken from the mother.  
The results indicated that out of the 5 microbes included, only gestational EV 
infections were statistically significantly associated with atopic outcome in the 
offspring. A gestational EV infection was detected in 17 (8%) mothers of the case 
children and in 53 (16%) mothers of the control children and it was inversely 
associated with atopic outcome in the offspring (OR: 0.43; 95% CI: 0.23-0.8; 
p=0.008) (Table 3). The result held true after adjusting for older siblings and furry 
pets, i.e. confounding factors found to associate with study outcome in univariate 
analyses (Table 4) (OR: 0.43; 95% CI: 0.23-0.81; p=0.009). Gestational IAV or M. 
pneumoniae infections or maternal seropositivity against CMV or H. pylori were not 
associated with atopic outcome in the offspring (Table 3).  
 
 
 
Table 3.  Prevalence (percentage in parenthesis) of maternal infections during pregnancy 
(enterovirus, Mycoplasma pneumoniae, influenza virus A) and cord blood 
seropositivity (Helicobacter pylori, cytomegalovirus) in Report II. 
 Case 
n=202 
Control 
n=333 
 
OR (95% CI) 
 
p value 
Enterovirus 17 (8) 53 (16) 0.43 (0.23-0.80) 0.008 
Mycoplasma pneumoniae 14 (7) 37 (11) 0.65 (0.34-1.22) 0.18 
Influenza virus A 26 (13) 43 (13) 1.05 (0.62-1.79) 0.86 
Helicobacter pylori 14 (7) 37 (11) 0.58 (0.30-1.12) 0.11 
Cytomegalovirus § 148 (74) 243 (74) 0.99 (0.66-1.47) 0.95 
CI, confidence interval; OR, odds ratio; § seropositivity in cord blood or first trimester serum sample. 
Associations with atopic outcome in the offspring are presented as OR and 95% CI.  
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Table 4.  Demographic characteristics of the study population in Report II.  
 
Case 
n=202 (%) 
Control 
n=333 (%) 
 
OR (95% CI) 
 
p value 
Gender (male) § 128 (63) 207 (62)   
HLA-DQB1 genotype §     
     DQB1 *02/*0302 18 (9) 30 (9)   
     DQB1 *0302/x ¤ 184 (91) 303 (91)   
Atopic disease      
     Asthma 52 (26)    
     Atopic eczema and/or rhinitis 126 (62)    
     Both # 24 (12)    
Older siblings (yes) 95 (47) 201 (60) 0.60 (0.42-0.86) 0.006 
Smoking in pregnancy (yes) 17 (9) 28 (8) 1.00 (0.53-1.89) 1.00 
Furry pets (yes) 58 (29) 146 (44) 0.53 (0.36-0.78) 0.001 
Maternal education     
     No secondary 50 (27) 98 (31) ref  
     Lower secondary 91 (48) 151 (48) 1.01 (0.65-1.59) 0.96 
     Higher secondary 48 (25) 63 (20) 1.26 (0.76-2.11) 0.37 
Paternal education     
     No secondary 86 (46) 144 (48) ref  
     Lower secondary 46 (25) 88 (30) 0.92 (0.59-1.44) 0.71 
     Higher secondary 56 (30) 66 (22) 1.34 (0.85-2.11) 0.21 
Duration of pregnancy † ¶ 280 (224-300) 280 (209-300) 1.01 (0.99-1.02) 0.53 
Birth weight † ~ 3650 (1910-4830) 3610 (1660-5540) 1.00 (1.00-1.00) 0.27 
OR, odds ratio; CI, confidence interval; §, case and control children were matched for sex and HLA-
DQB1 genotype; ¤, x refers to other alleles that *02, *0301 or *0602; #, both asthma and atopic eczema 
and/or allergic rhinitis; †, values are medians (minimum and maximum); ¶, presented in days; ~, 
presented in grams. Associations with the atopic outcome (diagnosis of asthma, atopic eczema and/or 
allergic rhinitis and aeroallergen IgE positivity) are presented as OR and 95% CI. 
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5.3 Enteroviruses detected in stool and atopic sensitization 
(Report III) 
In Report III, the possible association between EVs, and selected other viruses 
detected in stool, and IgE sensitization was investigated. Serial stool samples 
(n=4576) collected monthly from 244 children developing IgE sensitization and 244 
children remaining IgE negative were screened for the presence of RV, EV, NoV 
and HPeV RNA. The demographics of the study population are shown for the whole 
study cohort (Table 5) and separately for both sexes (Table 6). 
The results showed that RV was the most common virus detected with 921 (20%) 
of all samples positive for RV (Table 7). Altogether 371 (76%) children had at least 
one RV positive sample during the follow-up. The number of RV positive stool 
samples was inversely associated with IgE sensitization, but this phenomenon was 
observed only in boys. In other words, in the full cohort (both sexes) none of the 
viruses (RV, EV, NoV, HPeV) was statistically significantly associated with the 
atopic outcome. However, when the study cohort was stratified by sex, an inverse 
association between the number of RV positive samples and the atopic outcome was 
observed in boys; male controls had a significantly higher number of RV positive 
samples than male cases (Table 7). Sex did not influence the overall prevalence of 
RV infection, as the number of RV positive samples did not differ between boys and 
girls: 485 (21%) vs 436 (19%), respectively.  
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Table 5.  Demographic characteristics of the study population in Report III.  
 Case Control   
  n=244 (%) n=244 (%) OR (95% CI) p value 
Maternal atopy (yes) 72 (30) 72 (30) 1 (0.68-1.48) 1 
Paternal atopy (yes)  77 (32) 57 (23) 1.53 (1.02-2.29) 0.04 
Parental atopy     
      Neither 125 (52) 136 (56) ref  
      Either or both 117 (48) 108 (44) 1.18 (0.82-1.68) 0.37 
Older siblings (yes) 156 (64) 168 (69) 0.8 (0.55-1.17) 0.25 
Smoking inside (yes) 16 (7) 11 (5) 1.51 (0.69-3.34) 0.30 
Place of Residence     
      Urban 188 (79) 194 (81) ref  
      Rural 41 (17) 39 (16) 1.08 (0.67-1.76) 0.74 
      Both 9 (4) 8 (3) 1.16 (0.44-3.07) 0.76 
Type of Housing     
      Apartment 82 (34) 93 (38) ref  
      House or row house 118 (49) 127 (53) 1.05 (0.71-1.55) 0.79 
      Farm 16 (7) 8 (3) 2.27 (0.92-5.57) 0.07 
      More than one type 25 (10) 14 (6) 2.03 (0.99-4.15) 0.05 
Pets at home (yes) 106 (44) 98 (41) 1.14 (0.79-1.63) 0.49 
Entry in daycare § ¤ 612 (463-799) 601 (441-836) 1 0.97 
Cessation of  breastfeeding § ¤ 313 (154-392) 310 (148-382) 1 0.47 
Vaginal delivery (yes) 224 (92) 222 (91) 0.9 (0.48-1.7) 0.75 
Duration of pregnancy § #  281 (274-286) 282 (274-287) 0.99 (0.97-1) 0.10 
Birth weight § † 3610 (3228-3910) 3570 (3295-3884) 1 0.82 
OR, odds ratio; CI, confidence interval; §, values are medians (interquartile range); ¤, age of the child 
in days; #, presented in days; †, presented in grams. Associations with IgE sensitization are presented 
as OR and 95% CI. 
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Table 6.  Demographic characteristics of boys and girls separately (Report III) 
  Boys Girls 
 Case Control Case Control 
  n=140 (%) n=106 (%) n=104 (%) n=138 (%) 
HLA risk class     
      DR3-DQ2/DR4-DQ8 14 (10) 9 (9) 11 (11) 11 (8) 
      DR4-DQ8/x** 55 (39) 49 (46) 43 (41) 61 (44) 
      DR3-DQ2/y** 71 (51) 48 (45) 50 (48) 66 (48) 
Maternal atopy (yes) 42 (30) 30 (28) 30 (29) 42 (30) 
Paternal atopy (yes) § 41 (30) 26 (25) 36 (35) 31 (23) 
Parental atopy      
      Neither 72 (52) 60 (57) 53 (52) 76 (55) 
      Either or both 67 (48) 46 (43) 50 (49) 62 (45) 
Older siblings (yes) 89 (64) 73 (69) 67 (64) 95 (69) 
Smoking inside (yes) 9 (7) 5 (5) 7 (7) 6 (4) 
Place of Residence     
      Urban 112 (82) 78 (74) 76 (75) 116 (85) 
      Rural 19 (14) 22 (21) 22 (22) 17 (13) 
      Both 5 (4) 5 (5) 4 (4) 3 (2) 
Type of Housing     
      Farm 7 (5) 3 (3) 9 (9) 5 (4) 
      House or row house 70 (50) 55 (52) 48 (47) 72 (53) 
      Apartment 48 (35) 41 (39) 34 (33) 52 (38) 
      More than one type 14 (10) 7 (7) 11 (11) 7 (5) 
Pets at home (yes) 61 (44) 39 (38) 45 (44) 59 (43) 
Entry in daycare ¤ # 606 (458-814) 583 (423-828) 621 (475-783) 616 (449-841) 
Cessation of breastfeeding ¤ # 318 (154-398) 309 (147-370) 301 (154-379) 312 (150-390) 
Vaginal delivery (yes) 128 (91) 96 (91) 96 (92) 126 (91) 
Duration of pregnancy ¤ † 280 (272-286) 282 (274-286) 282 (275-286) 282 (275-288) 
Birth weight ¤ ¶ 3680 (3296-3966) 
3655 
(3341-3979) 
3470 
(3194-3788) 
3512 
(3265-3828) 
x** not DR3-DQ2 or a haplotype associated with protection against type 1 diabetes (T1D), y** not DR4-
DQ8 or a haplotype associated with protection against T1D, § in girls: odds ratio for IgE sensitization: 
1.85 (95% confidence interval: 1.05-3.28) p=0.03. ¤ values are medians (interquartile range), # age of 
the child in days, † presented in days, ¶ presented in grams. 
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Table 7.  Number of virus positive stool samples in boys and girls (Report III).  
 
 Case Control OR (95% CI) p value 
Rhinovirus total 429 (19) 492 (21) 0.91 (0.82-1.01) 0.09 
     Rhinovirus in boys 239 (19) 246 (24) 0.81 (0.69-0.94) 0.006 
     Rhinovirus in girls 190 (19) 246 (19) 1.02 (0.87-1.19) 0.83 
Enterovirus total 103 (5) 100 (4) 1.01 (0.80-1.20) 0.89 
     Enterovirus in boys 52 (4) 42 (4) 0.97 (0.70-1.30) 0.83 
     Enterovirus in girls 51 (5) 58 (5) 1.07 (0.80-1.40) 0.60 
Norovirus total 111 (5) 132 (6) 0.90 (0.70-1.10) 0.29 
     Norovirus in boys 58 (5) 59 (6) 0.80 (0.60-1.10) 0.19 
     Norovirus in girls 53 (5) 73 (6) 1.00 (0.70-1.30) 0.88 
Parechovirus total 92 (4) 102 (4) 0.90 (0.70-1.20) 0.55 
     Parechovirus in boys 56 (4) 51 (5) 0.90 (0.60-1.21) 0.43 
     Parechovirus in girls 36 (4) 51 (4) 1.00 (0.70-1.37) 0.80 
 
OR, odds ratio; CI, confidence interval. Altogether 4576 stool samples were analyzed, 2258 from 
cases and 2318 from controls. The number of virus-positive samples is shown (percentage in 
parenthesis). The association between the number of virus-positive samples and IgE sensitization is 
presented as OR and 95% CI. 
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The observed association between RV and atopy was also analyzed in different 
sensitization groups (see chapter 4.1.5.). The sex-dependent effect was observed in 
all of these 4 groups (Figure 3). Importantly, the effect was also observed when 
analyzing the association between the number of RV positive samples during the 
first 6 months of life and IgE sensitization developing later, after the age of 6 months 
(“late sensitized”): OR: 0.79; 95% CI: 0.60-0.94; p=0.016.  
 
 
 
 
 
 
 
Figure 3.  The association between the number of rhinovirus positive samples and IgE sensitization 
in groups with different IgE sensitization profiles (Report III). The results are shown as 
odds ratios and 95% confidence intervals. All, case children sensitized at 18 and/or 36 
months; early, case children sensitized at 6, 18 and 36 months; late, case children 
sensitized at 18 and/or 36 months but not at 6 months; aero, case children sensitized 
against aeroallergens; diet, case children sensitized against dietary allergens. 
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6 DISCUSSION 
All three reports in the current study provide new information about the relation 
between EVs and atopy in children. The results suggest that repeated exposure to 
different EV types as well as to RVs during early childhood is inversely associated 
with atopy. The study also suggests that EV infections may be important already in 
utero, as maternal EV infections during pregnancy were inversely associated with 
atopic disease in the offspring. As a whole, these results add new insight to the 
current knowledge about the role of EVs in the development of atopy. 
 
6.1 Enterovirus infections in early childhood and atopy 
The present study shows that cumulative exposure to different species A-D EV types 
during the first 2 years of life is inversely associated with atopic diseases. More 
specifically, this inverse association was related to cumulative seropositivity against 
different Es, whereas no association was observed with CVs.  
Previous research has linked EVs to the pathogenesis of T1D (38), another 
disease with an immunological background and a rapid increase in incidence over 
the recent decades. In addition, species A-D EVs replicate in the intestinal mucosa, 
and gut-associated immune system has been considered an important immunological 
compartment in the regulation of immune responses and induction of tolerance. 
These factors contributed to the current hypothesis that EVs might play a role in the 
development of atopy. Yet, existing data about EVs and atopy are scarce (7,10,11) 
and prospective studies focusing on EVs and atopy have been missing.  
In the present study, the inverse association between EVs and atopic illnesses 
varied according to the type of EV in question, which is in line with previous findings 
of our group. Seiskari et al detected that cumulative seropositivity against several non-
CV-B types was inversely associated with IgE sensitization in Russian Karelia (10). 
They also detected E11 seroprevalence to be more frequent in non-sensitized 
children than in IgE sensitized children (10). In the current study, the overall 
cumulative exposure to different Es was inversely associated with atopic disease but 
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no statistically significant associations between individual EV types and atopic 
disease were detected. This could be due to lack of statistical power as the EV 
seroprevalence in Finnish children of the present study was lower than that in 
Russian Karelian children studied by Seiskari et al. In addition, children in the study 
by Seiskari et al were older and thereby had likely encountered more EV infections 
than the younger children included in the present study. In the current study, the 
atopic endpoint was defined as having a physician diagnosed atopic disease in 
addition to IgE sensitization. This strict endpoint enabled focusing only on clinically 
relevant atopy but might have also led to missing some interesting associations. 
Finally, children in the present study lived in Finland where the overall standard of 
hygiene is better and microbial exposure lower than in Russian Karelia, which might 
have influenced the timing of EV infections. This comparison demonstrates that 
studying multifactorial diseases, such as atopic diseases, is complex and the results 
inevitably reflect features of the study population, outcome definition, laboratory 
method applied etc.  
However, similar to the results by Seiskari et al, this study showed that the 
protective association with atopy was especially related to Es and not to CVs (10). 
This finding has been further supported by Iwasaki et al, who reported the prevalence 
of E30 antibodies to be significantly lower in children with severe asthma than in 
non-asthmatic (11). It is known, that EVs differ from each other in their biological 
properties, such as tissue tropism, as well as their clinical manifestations. For 
instance, CV-Bs have been suggested to be especially important in myocarditis and 
pancreatic infections including a possible link to T1D (38), whereas EV-A71 and 
CV-A16 are important pathogens in HFMD (36). It is also possible that Es and CVs 
differ in terms of e.g. cell entry mechanisms, target cells, evasion from the host 
immune system or prevalence in the infant’s environment. In fact, a recent study 
identified neonatal Fc receptor as a pan-echovirus receptor that did not bind CVs or 
PVs (149). This Fc receptor is expressed on the placenta, but also throughout life e.g. 
in the small intestine, hepatocytes and endothelium of the blood-brain barrier (149). 
The protective effect associated with some EV types might also be related to possible 
immunomodulatory effects of these viruses. Es have been shown to infect DCs in 
vitro, unlike CV-Bs (150). In another study, different CV-B1 strains varied 
considerably in their interaction with plasmacytoid DCs and in the immune 
activation profile they induced (151). However, currently the biological basis of the 
observed difference between Es and CVs in relation to atopy remains speculative.  
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6.2 Gestational enterovirus infection and atopy 
In the present study, a novel finding of maternal EV infection during pregnancy 
associating with a reduced risk of atopic disease in the offspring was observed. There 
are only a few previous studies evaluating the possible role of gestational infections 
in the development of atopic disease by analyzing laboratory-confirmed infections 
and these few studies have focused mainly on bacterial or helminth infections (135-
137,139). Laboratory-confirmed viral infections during pregnancy have been 
analyzed only in one prior study (138). In that study, samples from asthmatic 
mothers with respiratory infectious symptoms were analyzed by PCR against a panel 
of common respiratory viruses. The authors report that the risk of asthma and 
eczema at the age of 1 year was increased in children born to mothers with PCR-
confirmed viral infection when compared to mothers with common cold symptoms 
without laboratory-confirmed infection (138). EVs were also included in the 
microbial panel but they were detected in only 3 of the 42 samples taken (138). 
Therefore, reliable conclusions about the role of EVs in the development of atopy 
in the offspring cannot be drawn from that study. 
In contrast to the current study, most previous studies have relied on 
questionnaires or medical records in defining infections. This approach does not 
allow the distinction of possible microbe-specific differences, and questionnaire-
based studies are also susceptible to recall bias. In addition, only symptomatic 
infections are recorded and thereby a major part of microbial exposures might go 
unrecognized. This is particularly true for EVs since the majority of EV infections 
are subclinical. Serological assays, such as the ones applied in this study, capture both 
symptomatic and silent infections and are thus more sensitive tools in evaluating 
microbial exposure. On the other hand, with no information about maternal 
infectious symptoms, the current study was unable to address possible differences 
between symptomatic and asymptomatic infections and their relation with atopy.  
In addition to EVs, selected other microbes, i.e. IAV, M. pneumoniae, CMV and H. 
pylori, were also included in the microbial panel in the present study. However, 
gestational EV infection was the only one with a statistically significant association 
with atopy in the offspring. One explanation for this difference might lie in the route 
of infection. EVs are transmitted mainly orofecally and gastrointestinal pathogens 
have been reported to inversely relate with atopy (108,109), but the results are not 
uniform (110,111) leaving the issue unresolved. Further, H. pylori is also a 
gastrointestinal microbe and postnatal H. pylori infection has been shown to inversely 
associate with atopy in some studies (152). However, in the current study no 
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association between maternal H. pylori infection and atopy in the offspring was 
observed. This could partly be due to the low number of H. pylori positive mothers, 
which might have resulted in insufficient statistical power to detect subtle 
associations. Nevertheless, the results suggest that microbes differ in their effect on 
the development of atopy and EVs appear to be especially interesting in this respect. 
The possibly special nature of gestational EV infections is further supported by the 
findings of a recent meta-analysis reporting EV infections during pregnancy to 
increase the risk of T1D in the offspring (153).  
The mechanisms of how gestational EV infections might influence the 
offspring’s susceptibility to atopic disease are not known. In general, maternal viral 
infections during pregnancy can affect the fetus in several ways. Several viruses can 
cross the placental barrier and infection of the fetus can have severe consequences 
(154). Maternal EV infection during the first trimester has been associated with early 
fetal loss and infection in late pregnancy has resulted in clinical EV disease in the 
newborn infant (155). EVs are also capable of infecting the placenta, as shown by 
Satosar et al who detected EVs in a marked proportion of placentas obtained from 
pregnancies with severe neonatal morbidity (156). Thus, also in the current study an 
EV infection in the placenta-fetal unit is possible. However, in such case the 
infections did not cause severe fetal manifestations as neither the duration of 
pregnancy nor the birth weight of the newborn infant differed between pregnancies 
with and without maternal EV infection (data not shown). 
In addition to infecting the fetus or the placenta, microbes could also affect the 
fetus through a local inflammatory response in the placenta or activation of maternal 
systemic immune responses. These immunological effects could modify the fetus’ 
cytokine balance and influence the maturation of the immune system. As an 
illustration, there are data suggesting that prenatal environmental factors might affect 
the offspring’s risk of atopy through changes in innate immunity. Maternal exposure 
to farming has been shown to increase gene expression of certain TLRs in cord 
blood cells (88), and increased expression of TLR genes at birth has in turn been 
associated with a reduced risk of atopic eczema in the offspring (90). Additionally, 
different microbes are known to activate different types of TLRs (84).  
Recent observations about the neonatal microbiota have opened an intriguing 
new area in atopy research. Although speculatively, one might hypothesize that also 
gestational infections could have an impact on the microbiota of the newborn. It is 
becoming increasingly evident that the intrauterine environment is not sterile, as 
bacteria have been detected from placenta, amniotic fluid and the newborn infant’s 
first intestinal discharge (meconium) (104-106,157). Fetuses continuously swallow 
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amniotic fluid, and meconium has been shown to harbor a microbial composition 
similar to amniotic fluid and placenta (105) and thus, the meconium microbiota has 
been suggested to reflect the in utero environment (106). Maternal bacterial infections 
during the first trimester have been shown to associate with distinct shapes of 
placental microbiome that might further influence the microbial composition of 
meconium (104). Most data have focused on bacterial microbiota but there are some 
emerging data about human enteric virome and its role in host health and disease 
(158). EVs might be potent pathogens in contributing to the enteric virome, as they 
often replicate in the gut for a relatively long time after an infection. Currently it 
seems that viruses constitute only a minority of the human gastrointestinal 
microbiota but there is some data indicating that intestinal viruses and bacteria might 
interact with each other (159,160). For instance, results from mouse studies suggest 
that optimal infectivity of poliovirus, a member of the EV C species, depends on the 
presence of concomitant bacteria in the gut (161).  
 
6.3 Rhinovirus exposure and atopic sensitization  
The results from this study suggest a sex-based difference in the effects of early RV 
exposure; RV positive stool samples during the first year of life were found to 
inversely associate with IgE sensitization in boys. In this study, RVs were analyzed 
from stools, which is an unconventional method in measuring RV exposure in allergy 
research. The results offer novel insights into the role of RVs in the development of 
atopy.  
In addition to RVs, selected other viruses were included in the analysis, i.e. species 
A-D EVs, NoVs and HPeVs, but they were not associated with atopic sensitization. 
Reports I and II showed an inverse association between species A-D EVs and atopic 
disease, which was not observed in the present study (Report III). This is most likely 
due to methodologic differences. RT-qPCR is a direct virus detection method and 
due to the transient nature of EV RNA in feces, the results are highly dependent on 
the timing of sampling. In contrast, serology is less dependent on timing, as virus 
antibodies are detectable in the serum for months or years after the infection. 
Additionally, the RT-qPCR test applied did not enable distinction between Es and 
CVs, which might have had an impact on the results as suggested by Report I and 
previous studies (10,11). For NoVs, the current study reinforces previous results 
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where no association between NoV seropositivity and IgE sensitization was detected 
(111). 
Although RVs have not been analyzed from stool samples in allergy studies 
previously, there are prior data about RV detection in stool. Harvala et al were able 
to detect all three RV species in stool, and they also observed that RV positive 
samples were most frequent in children under 2 years of age (162). Species C RVs 
have also been detected in stool in children hospitalized for gastroenteritis, also in 
the absence of respiratory symptoms (163). Honkanen et al found RVs to be frequent 
in stool samples collected prospectively from young children by applying the same 
RT-qPCR method as in the current study (164).  
In the present study, RVs were frequent in stool samples during the first year of 
life with 20% of samples positive for RV RNA. Honkanen et al detected a slightly 
lower prevalence with 14% of stool samples positive for RVs (164, oral 
communication). However, in that study fecal sample collection started at the age of 
3 months, whereas in this study collection started already at the age of 1 month. In 
the present study, RV positive samples were most frequent during the first 6 months 
of life and this might partly confer to the slightly higher prevalence observed. RVs 
have been shown to be abundant in stool in children also previously, as RVs were 
detected in 35% of fecal samples taken during acute infections (165). 
The reasons for the high frequency of RVs in stool are not known. RVs are 
respiratory viruses replicating in the nasal and nasopharyngeal epithelia and they are 
commonly detected in nasal samples during upper respiratory tract infections 
(42,166). RVs are generally considered not to infect the gastrointestinal tract, as they 
degrade in the low pH of the stomach due to their acid sensitive capsid (167). In 
addition, RVs grow best on cell cultures at temperatures of 33-35ºC, equaling that 
of the intranasal temperature. However, the acid sensitivity of RVs might not be 
particularly stable, as only a single amino acid change in the RV capsid protein has 
been shown to be sufficient to confer resistance to inactivation in low pH (168). 
Furthermore, the pH of the stomach in young infants is higher than in older children 
or adults (169), which might enable the preservation of RVs in the gastrointestinal 
tract in this age group and explain the high frequency of RV positive samples among 
the youngest subjects in the present study. There is also an in vitro study showing 
that, unlike previously thought, the replication of some RVs was only minimally 
decreased at 37ºC as compared to replication at 33ºC (51). Taken together, detection 
of RVs in stool can reflect either a passive drift of RVs from the respiratory tract to 
the gut without marked degradation in the stomach, or active replication of RVs in 
the gastrointestinal tract, or perhaps both. Nevertheless, gastrointestinal tract 
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replication of RVs has not been proved and the passive drift phenomenon seems at 
present a more plausible explanation for detecting RVs in stool.  
In the current study, the inverse association between RV positive samples and 
IgE sensitization was detected only in boys. This is interesting since sex can affect 
susceptibility to a wide range of infections and immune-mediated diseases. In 
general, the severity and prevalence of many infections, including viral infections, is 
higher in males (170,171). For instance, boys are more susceptible to severe forms 
of EV infections, such as myocarditis (172). In a study by Uekert et al, boys were 
shown to have more moderate-to-severe RV illnesses during early childhood, as well 
as higher IFN-γ responses (173). They also observed boys to be more often IgE 
sensitized, which is in line with results from other studies (174). These data do not 
provide direct explanations to the sex-based difference in the present study but 
rather suggest that sex might have a diverse effect on immune functions. For 
instance, the effect of parental atopy on the offspring’s risk of atopy was shown to 
depend on the sex of the child; maternal atopic history increased the risk of atopic 
diseases in girls and paternal history in boys, whereas the effect of the parent from 
the opposite sex was insignificant (175). Another study reported that dog exposure 
during the first year of life was inversely associated with IgE sensitization against 
dogs only in males (176). There are also indications that sex-based differences might 
be present already at birth, since boys were shown to have lower Treg numbers as 
well as TLR1 and TLR2 gene expression in cord blood than girls (88,177). In 
conclusion, the biological mechanism behind the sex-based effect observed in the 
present study remain to be elucidated but this finding together with previous results 
suggests that sex might be one important factor in the pathogenesis of atopic 
diseases.  
 
6.4 Enteroviruses and atopy – protection or predisposition? 
The data from the current study suggests that species A-D EV infections in early 
childhood and during pregnancy are inversely associated with atopic disease, which 
supports their role as possible protective factors. This is in line with the concept of 
hygiene hypothesis. However, it is possible that the effect is not limited to these 
specific pathogens but instead a broader insight should be adapted when interpreting 
the results. For example, in the present study, one possibility is that EV infections 
might in fact be a surrogate marker for some other known or unknown 
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environmental factor, either predisposing to EV infections or occurring 
concomitantly.  
For RVs, abundant data show that RV-induced wheezing predisposes to the 
development of asthma (178). However, most previous research has focused on RV-
induced wheezing and asthma, and data about RVs and other atopic diseases or IgE 
sensitization per se are scarce. Jartti et al observed in a cross-sectional setting an 
association between wheezing RV illness and IgE sensitization (114) but later, a 
prospective study reported that RV-induced wheezing did not predispose to 
aeroallergen sensitization (122). Th2-type cytokines IL-4 and IL-13 have been shown 
to impair the innate immune response to RVs suggesting that children with atopic 
diseases might have altered RV immunity (179). In addition, polymorphism in the 
CDHR3 locus might predispose some children to more severe RV-C infections and 
asthma (49,121). The complex interplay between IgE sensitization and RV infection 
is also illustrated in a study where IgE-mediated reactions were blocked by 
omalizumab (an anti-IgE antibody), which resulted in fewer and milder respiratory 
RV infections (180). Taken together, it has been demonstrated that IgE sensitization, 
and wheezing RV infections predispose to childhood asthma both independently 
and synergistically, but the nature of the interaction between IgE sensitization and 
RV infection remains less known.  
RV-induced wheezing represents just one form of RV infection and some data 
suggest that asymptomatic or mild RV infections might differ from severe ones in 
relation to atopy (119). Jackson et al reported that severe wheezing RV infections 
increased the risk of asthma but no association between asthma and RVs detected 
from nasal samples during prescheduled visits was detected (119). However, they 
included data only from a few clinic visits per child, whereas in the current study 
monthly analysis of stool samples was performed. In the light of previous and 
present data, it could be hypothesized that asymptomatic or mild RV infections 
might serve a beneficial function in driving postnatal immune maturation, thereby 
reducing the risk of allergic sensitization, whereas severe RV infections resulting in 
wheezing might increase the risk of asthma. 
 
6.5 Genetic aspects 
The study subjects in the present study were selected among the participants of 
ongoing studies with a primary focus on T1D. Therefore, the cohorts in the current 
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studies comprise of children with T1D-associated HLA genotypes, which could have 
influenced the results. In fact, some studies have linked HLA-DQ region with 
asthma and HLA-DRB1 region with IgE sensitization (181,182). However, as the 
genetic background of atopy is highly polymorphic and it has been estimated that 
HLA-DRB1 locus only accounts for 2-3% of the variation in specific IgE titers (181), 
it is unlikely that the HLA selection would have substantially influenced our results. 
Furthermore, the case and control groups were matched for the T1D-associated 
HLA genotypes (Reports I and II).  
 
6.6 Methodological aspects 
In this study, EVs were analyzed by two different serological methods; detection of 
NABs in Report I and detection of IgG class antibodies by EIA in Report II. NABs 
are long lasting and serotype-specific, which makes analyzing NABs especially useful 
in seroprevalence studies on a population level. In Report II, acute maternal EV 
infections were diagnosed by an increase in IgG antibody levels between maternal 
first trimester serum sample and cord blood. The EV antigen applied has been 
shown to detect antibodies against a wide range of EV types (143,144). The interval 
between paired serum samples was longer than usually applied in clinical diagnostics 
but since IgG responses usually last for several month or years, it is probable that 
the current method was able to detect infections reliably.  
RVs were analyzed from stool samples by RT-qPCR. As with all PCRs, avoiding 
contamination is crucial for the reliability of results. In the present study, 
contamination of the samples is unlikely since virus negative control samples (sterile 
water) were included in every PCR run and they remained negative. The qPCR 
method applied is highly sensitive, which was also confirmed in the blinded test runs 
of external quality control samples provided by Quality Control for Molecular 
Diagnostics (QCMD). As some RV PCR methods have been shown to detect also 
EVs (162), the possibility of false positive reactions due to cross-detection of EVs 
by RV PCR must also be considered. However, in a study comparing the 
performance of different PCR primers in the detection of RVs, the primers used in 
the PCR analysis in Report III did not amplify any EVs included (183). In Report 
III, the specificity of the PCR reaction was further increased by applying a RV 
specific probe. In addition, the QCMD blind tests showed that the RT-qPCR 
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method used in the present study, did not amplify EV-D68, one of the closest 
phylogenetical relatives of RV.  
 
6.7 Limitations of the study 
Even though the prospective study setting enabled the identification of temporal 
relations between viral exposure and atopic outcome, interpretation of a possible 
causal relationship should be made with caution. This is true especially in Report I, 
where data about the exact age of the child at the time of IgE sensitization or 
diagnosis of the atopic disease were not available and therefore the time order of the 
events could not be addressed. In other words, some children might have developed 
atopy already before EV infections. In addition, the current study did not address 
the biological mechanisms behind the associations observed, which further hinders 
from drawing strong conclusions about causality.  
The background information was limited to the data collected within the routine 
DIPP and Diabimmune study protocols. Thereby some potentially interesting and 
relevant information might have been missed. Especially in Reports I and II, data 
about the parental history of atopy would have allowed studying the associations 
between EVs and atopy with respect to different genetic backgrounds. In addition, 
the lack of nasal samples in Report III prevented the possibly interesting comparison 
between RVs in simultaneously collected stool and nasal samples.  
The study subjects were selected for T1D-related HLA genotypes, which could 
have influenced the generalizability of the results. Other possible limitations 
concerning the HLA selection in this study are discussed in chapter 6.5. “Genetic 
aspects”. In addition, there might be inherent weaknesses in laboratory methods 
applied and even though the laboratory methods were carefully optimized and 
controlled, this possibility cannot be completely excluded. The limitations of the 
methods are discussed further in chapter 6.6. “Methodological aspects”.  
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7 CONCLUSION AND FUTURE PROSPECTS 
The main aim of the present study was to evaluate the possible relation between EV 
infections and atopy. This was addressed by studying different aspects of species A-
D EV and RV infections in early life. The study utilized serum and stool samples 
collected in two different prospective birth cohorts and EVs were tested by serology 
(neutralization assay or EIA) or by detecting viral RNA (RT-qPCR). 
Taken together, this study showed that EV infections in early life are inversely 
associated with atopy. More specifically, this was observed when studying cumulative 
seropositivity against different EV types in early childhood and maternal EV 
infections during pregnancy, both of which were inversely associated with atopic 
disease. In addition, the number of RV positive stool samples during infancy was 
inversely associated with subsequent IgE sensitization in boys. Thereby, the results 
from this study support the hygiene hypothesis and reinforce it with new data about 
some of the less-studied pathogens. As the prevalence of atopic diseases is high and 
continues to increase in many parts of the world, providing new data that might 
eventually contribute to the prevention of these common illnesses is of value. 
It seems clear that atopic diseases develop as a result from a complex interplay 
between cumulative environmental factors and genetic susceptibility. Studying such 
multifactorial diseases is challenging since it is important to both adequately control 
for the known confounders and to discover new relevant connections. Prospective 
follow-up studies enabling the identification of causal relationships are ideal but 
demand a considerable amount of resources. However, it is of equal value to gain 
new data about the biological mechanisms behind the associations as it enhances the 
more in-depth understanding of the pathogenesis of atopic diseases. In addition, 
emerging new data about the role of microbiota, both individual and environmental, 
special characteristics of the in utero period, pheno- and genotyping of atopic diseases 
and uncovering gene-environment interactions etc, offer numerous new areas for 
future research.  
The results from this study provide further support to the earlier observations 
that the nature of early microbial exposure is important and EVs continue to be 
interesting pathogens in the development of atopy. In the future, it would be of value 
to combine data about EV infection during prenatal and early postnatal period and 
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study the combined effect in more detail. The results from this and previous studies 
also emphasize the possible serotype-specific differences of EVs, and possibly also 
RVs, and addressing this question further would be of interest. Especially with regard 
to RVs, analyzing prospectively collected nasal and stool samples, and ideally 
genotyping the viruses, would provide important new data. Further, novel molecular 
methods, such as next-generation sequencing, could be applied to try to identify 
features of the microbiota that might, independently or together with EV infections, 
confer to the development of atopy. In the future, a more detailed knowledge about 
the role of viruses and other microbes in atopic diseases might enable the 
development of interventions conferring the immunomodulatory effects of these 
microbes, ideally resulting in prevention of these common diseases.  
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Summary
Background Enterovirus infections in childhood have been associated with a reduced risk
of atopy in cross-sectional studies.
Objective To study the relation between enterovirus infections in the ﬁrst 2 years of life
and atopic disease with IgE sensitization in a prospective study setting.
Methods This was a nested case-control study among children who had been followed
from birth. Neutralizing antibodies against 12 enterovirus serotypes were analysed at the
age of 2 years from 71 atopic children and 142 non-atopic control children. Atopy was
deﬁned as having an atopic disease and IgE antibodies against at least one aeroallergen
by the age of 5 years.
Results Cumulative exposure to different enterovirus serotypes was inversely associated
with atopy [odds ratio (OR) 0.73; 95% conﬁdence interval (CI): 0.56-0.96]. The most pro-
nounced protection was seen when echoviruses were analysed as a separate group (OR
0.63; 95%CI: 0.46–0.88).
Conclusions and Clinical Relevance We propose that exposure to several different entero-
viruses in early childhood is inversely associated with atopic diseases. Our results support
the hypothesis that repeated microbial infections in early life may protect from atopic
sensitization and atopic diseases.
Keywords allergy, atopic disease, atopic sensitization, atopy, enterovirus, hygiene hypoth-
esis, neutralizing antibodies
Submitted 15 May 2012; revised 27 October 2012; accepted 26 November 2012
Introduction
The prevalence of atopic diseases in childhood is high
in most Western industrialized countries and the
increasing trend is still continuing [1]. Also in Finland,
the prevalence of atopic diseases, such as asthma and
allergic rhinitis, as well as IgE sensitization has
increased manifold in recent decades [2, 3]. According
to the “hygiene hypothesis” this increase is related to a
reduced microbial load in early childhood [4]. Numer-
ous studies have provided indirect evidence to support
the hypothesis, as growing up on a farm [5, 6], having
one or more older siblings [4, 5, 7] and early atten-
dance in daycare [8] have been shown to be associated
with protection from allergy. It has also been reported
that geographically adjacent but socioeconomically
contrasting countries differ markedly in the prevalence
of allergic sensitization [9–11]. However, direct obser-
vations of the role of microbial infections in the devel-
opment of atopic diseases have been somewhat
controversial [12].
Viruses could theoretically be highly effective
microbes in preventing atopy, as they induce a strong T
helper (Th) 1 type immune response, which might sup-
press the excessive Th2 immune response often seen in
atopic diseases. In fact, certain viral infections, such as
hepatitis A virus, Epstein Barr virus, varicella zoster
virus, and measles [13–16], have been associated with
lower risk of atopic diseases and allergic sensitization.
However, there are also studies reporting conﬂicting
results [17–20].
The possible protective effect conferred by infections
may depend on their timing [12]. Early life has been
proposed as an especially favourable period for protec-
tive microbial contacts [6, 14, 15, 21]. The route of
exposure to microbial antigens may also be critical. The
gut is believed to be an important organ in the early
development of immunological tolerance and accord-
ingly, previous studies suggest that orofecally transmit-
ted infections are especially potent in protecting from
allergic sensitization [22–24].
Enteroviruses are small RNA viruses comprising
almost 100 serotypes. They are traditionally classiﬁed
into echoviruses, coxsackie A and B viruses, and poli-
oviruses. Vaccination against polio serotypes has almost
eradicated wild-type polioviruses, while other enterovi-
rus serotypes are common world-wide. Enterovirus
infections are frequent from early infancy onwards.
They are mainly subclinical or cause only mild upper
respiratory tract infections, gastroenteritis or non-spe-
ciﬁc febrile illnesses, although severe manifestations,
such as meningitis and myocarditis, also occasionally
occur. Enteroviruses are transmitted mainly orofecally
and replicate primarily in the gut. They have also been
linked to the pathogenesis of type 1 diabetes [25],
another disease with a rapidly increasing incidence over
recent decades [26]. As the concept of hygiene hypothe-
sis has recently been extended from allergies to other
immune-mediated disorders including autoimmune dis-
eases such as type 1 diabetes [27], we hypothesized that
enteroviruses might also modulate the risk of atopic
diseases. This presumption has recently been reinforced
by our own studies showing an association between
enterovirus infections and a lower prevalence of atopy
in a cross-sectional setting [11, 28].
In this study, we wanted to investigate the relation
between enteroviruses and atopic diseases in a nested
case-control setting based on the prospective Diabetes
Prediction and Prevention (DIPP) Study. Furthermore,
we set out to study the importance of different entero-
virus serotypes in atopic diseases.
Methods
Study population
The study population was derived from the DIPP Study,
initiated in Finland in 1994. The basic design of the
DIPP study has been described in detail elsewhere [29].
Brieﬂy, newborn infants at the University Hospitals in
Turku, Oulu and Tampere were screened at birth with
parental consent for type 1 diabetes associated HLA-
DQB1 alleles [30]. The designated HLA-DQB1 risk geno-
types are present in about 15% of the Finnish popula-
tion [31]. Infants with these designated HLA-DQB1 risk
alleles were invited to enter the DIPP study follow-up
with regular visits to the DIPP study clinic with an
interval of 3–6 months for the ﬁrst 2 years of life and
thereafter with an interval of 6–12 months. At each
visit, the children underwent a comprehensive interview
and a clinical examination, and a venous blood sample
was taken. Serum samples were stored at 70°C in the
DIPP study biobank. Data about diagnosed atopic dis-
eases, parental education, attendance in daycare, pets at
home, and siblings were asked regularly and recorded
in the DIPP database.
For this study, a cohort of children was selected as
follows. In spring 2009, we screened all DIPP children
born in Tampere University Hospital between January
1, 1998 and December 31, 2003 for the physician-set
diagnosis of bronchial asthma, atopic dermatitis, or
allergic rhinitis. Age of the children at the time of the
screening ranged from 5 to 11 years. The diagnoses had
been made according to national guidelines and they
had been recorded in the DIPP database. Only children
with serum samples taken during the DIPP follow-up at
the ages of 1, 2, and 5 years were eligible for the study.
Children with type 1 diabetes associated autoantibodies
and/or type 1 diabetes were excluded. Eligible children
were then screened for IgE antibodies against a mixture
of aeroallergens from the serum samples taken at the
age of 5 years. The serum samples for IgE analyses
were obtained from the DIPP study biobank. Children
who had both an atopic disease and IgE antibodies
comprised the group of case children. For each case
child, two control children having neither a diagnosis
of an atopic disease or IgE antibodies against aeroaller-
gens were chosen. The case and control children were
matched for the time of birth, gender, and HLA-DQB1
alleles.
Information about parental education, pets at home,
number of older siblings, and child’s age at the begin-
ning of daycare was obtained from the DIPP database.
Data about maternal smoking during pregnancy were
received from the Finnish birth register.
This study was carried out within the DIPP cohort
born in Tampere University Hospital. The DIPP study
protocol has been approved by the ethical committee of
the Tampere University Hospital (Tampere University
Hospital approval number ETL 97193M).
IgE antibodies
IgE measurements were made from serum samples
taken at the age of 5 years. IgE antibodies against a
mixture of common airborne allergens [a multi-allergen
© 2012 John Wiley & Sons Ltd, Clinical & Experimental Allergy, 43 : 625–632
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test (Phadiatop®, Thermo Fisher Scientiﬁc, Uppsala,
Sweden) containing allergens of birch, timothy, mug-
wort, cat, dog, horse, Dermatophagoides pteronyssinus,
Cladosporium herbarum] were measured using the Im-
munoCAP® enzyme immunoassay (Thermo Fisher Sci-
entiﬁc, Uppsala, Sweden) according to manufacturer’s
protocol. Values of 0.35 kU/L or more against the aller-
gen mixture were considered positive.
Virus strains
The ATCC (American Type Culture Collection) reference
strains of enteroviruses [coxsackievirus B2 (CBV2), cox-
sackievirus B6 (CBV6), echovirus 9 (EV9), echovirus 11
(EV11), echovirus 30 (EV30)] as well as wild-type
enterovirus isolates from Finland [coxsackievirus A9
(CAV9), coxsackievirus B1 (CBV1), coxsackievirus B3
(CBV3), echovirus 3 (EV3), echovirus 5 (EV5), echovirus
21 (EV21), echovirus 26 (EV26)] were used in this study.
Cell lines
A continuous cell line from African green monkey kid-
neys (GMK cells) was used for virus propagation. Cells
were grown in minimal essential medium supplemented
with foetal bovine serum (10% for cell growth, 1% for
virus propagation), 15 mM Hepes, pH 7.4 and 15 mM
MgCl2. A549 cell line from human alveolar adenocarci-
noma was used for EV30 virus propagation.
Plaque neutralization assay
Serum samples taken at 1 and 2 years of age were
available from each case and control child to be used
for the classical plaque neutralization assay [32]. This
method measures antibodies in a serotype-speciﬁc man-
ner against the enterovirus serotypes included in the
assay. Neutralizing antibodies remain elevated for sev-
eral years or decades reﬂecting the past infection his-
tory of the child. The serum samples taken at 2 years of
age were analysed for the presence of neutralizing anti-
bodies against each of the 12 enterovirus serotypes
studied. The 1-year samples were analysed for echovi-
rus serotypes 3, 5, 9, 11, and 30. In the assay, a four-
fold dilution of serum was mixed with an equal volume
of pretitrated virus (~100 plaque-forming units in 6 lL)
and allowed to react for 1 h at 36°C followed by an
overnight incubation at room temperature. After addi-
tion of the virus propagation medium, the sample was
placed on monolayers of GMK cells or A549 cells on
six well plates, density of ~0.8 9 106 cells per well.
After 30 min incubation at 36°C, 2 mL of plaquing
overlay (cellulose in the virus propagation medium)
was added. The amount of infectious virus was detected
by counting the plaques after 2 days of incubation at
36°C. The serum was considered antibody positive if it
blocked more than 80% of the virus infectivity.
Statistical methods
Conditional logistic regression analysis was used to
determine the association between enterovirus infections
and atopic diseases in the matched data. The results are
presented as odds ratios (OR) and 95% conﬁdence inter-
vals (CI) for atopic diseases. Conditional logistic regres-
sion analysis was applied when comparing the
association for each serotype individually, for having
antibodies against at least one enterovirus serotype, for
the cumulative prevalence of enterovirus antibodies and
for confounding factors. Categorized variables were used
for confounding factors: pets at home (no pets vs. at
least one indoor pet of any kind), maternal education
(no professional training or lower secondary training vs.
higher secondary or tertiary training), paternal education
(no professional training or lower secondary training vs.
higher secondary or tertiary training), maternal tobacco
smoking during pregnancy (no vs. yes), and having older
siblings (no older siblings vs. at least one older sibling).
A continuous variable was used for the attendance in
daycare (number of months in daycare before the diag-
nosis of an atopic disease was recorded in the DIPP data-
base). Conditional logistic regression analysis was
applied when determining the association between indi-
vidual confounders and atopic diseases. All analyses
were performed using STATA 8.2 (Statacorp, College
Station, TX, USA).
Results
A total of 2942 infants born in Tampere between Janu-
ary 1, 1998 and December 31, 2003 entered the DIPP
study and 1852 (63%) stayed in the follow-up for at
least until the age of 5 years. One hundred eighty-three
children had a diagnosis code for an atopic disease and
blood samples taken at the ages of 1, 2, and 5 years. 71
(39%) of them were IgE positive for aeroallergens at the
age of 5 years. The case children having both a diag-
nosed atopic disease and IgE sensitization (n = 71)
included 28 (39%) girls and 43 (61%) boys. Thirty-
seven (52%) of the case children had atopic dermatitis,
29 (41%) bronchial asthma, and 5 (7%) allergic rhinitis.
The median age when the atopic disease was recorded
in the DIPP database was 22 months (range 2–
102 month). There were 142 control children matched
for age, gender, and HLA-DQB1 genotype. The median
age difference between cases and controls was 9 days
(range 0–64 days) and 14% of them had the HLA-DQB1
*02/*0302 genotype and 86% had the *0302/x geno-
type (x referring to other alleles than *02, *0301 or
*0602).
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Data about pets were available from 209 (98%),
maternal tobacco smoking from 204 (96%), maternal
education from 206 (97%), paternal education from 194
(91%), older siblings from 209 (98%), and attendance in
daycare from 194 (91%) children. There were no statis-
tically signiﬁcant associations between the confounders
analysed and atopy.
Neutralizing antibodies against 12 different enterovi-
rus serotypes were measured from the serum samples
taken at the age of 2 years. The prevalence of neutraliz-
ing antibodies against different enterovirus serotypes
varied greatly (Fig. 1). Sixty-one (85.9%) case children
and 119 (83.8%) control children had neutralizing anti-
bodies against one or more enterovirus serotypes
(p = ns). However, the control children were seroposi-
tive against a higher number of different enterovirus
serotypes as compared with the cases (OR: 0.73; 95%CI:
0.56-0.96; p = 0.025) (Fig. 2a).
For subgroup analyses, the enteroviruses were
divided into echovirus and coxsackievirus groups.
Fifty-three (74.7%) case children and 111 (78.2%) con-
trol children had neutralizing antibodies against one or
more echovirus serotypes (p = ns). The control children
were seropositive against a higher number of different
echovirus serotypes as compared with cases (OR: 0.63;
95%CI: 0.46–0.88; p = 0.006) (Fig. 2b). In the coxsac-
kievirus group, 25 (35.2%) and 45 (31.7%) of case and
control children, respectively, had antibodies against at
least one serotype (p = ns). The number of neutralizing
antibodies against different coxsackievirus serotypes
did not differ between cases and controls.
To study the early encounters with enteroviruses,
additional measurements of neutralizing antibodies
against ﬁve echovirus serotypes (EV3, 5, 9, 11 and 30)
were carried out from serum samples obtained at the
age of 1 year. For most of these serotypes, antibody
positivity was slightly more frequent among the control
children, but no statistically signiﬁcant difference was
seen in any individual serotype (Fig. 3a). When the
number of neutralizing antibodies in each child was
analysed at the age of 1 year, we did not observe any
association between the accumulation of infections by
different echovirus serotypes and protection from atopy
(OR: 0.77; 95%CI: 0.54–1.10; p = ns), although this
protective effect was seen at 2 years of age (Fig. 2b).
However, 98 (69.0%) control children but only 39
(54.9%) case children had neutralizing antibodies
against any echovirus serotype (OR: 0.52; 95%CI: 0.28–
0.96; p = 0.038)(Fig. 3b).
Discussion
In this study, we found an inverse association between
the cumulative exposure to enteroviruses and atopic
diseases with IgE sensitization. More speciﬁcally, this
ﬁnding seemed to be related to echoviruses only.
Already at the age of 1 year, case children had a lower
prevalence of echovirus antibodies and by the age of
2 years they were seropositive against a lower number
of echovirus serotypes. This suggests that exposure to a
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high number of different echoviruses during the ﬁrst
years of life might protect from atopic diseases.
There are only a few previous reports on the role of
enteroviruses in atopy [11, 28, 33, 34], and to our
knowledge, no earlier studies have been carried out in a
prospective setting. In a cross-sectional study, seroposi-
tivity against enteroviruses protected from atopic sensi-
tization in Russian Karelia but not in Finland [11].
However, in that study enterovirus antibodies were
measured from older children using an EIA assay, a
method known to lack serotype speciﬁcity. In a more
recent study from the Russian Karelia, the presence of
neutralizing antibodies against echoviruses was associ-
ated with a reduced risk of IgE sensitization in school-
children [28]. This is in line with our results from this
study carried out among very young children, suggest-
ing that enterovirus infections are associated with lower
risk of atopy and that enterovirus serotypes differ in
terms of their effect on atopic diseases. These ﬁndings
further emphasize the advantages of serotype-speciﬁc
assays in studies evaluating the possible role of entero-
viruses in atopic sensitization and atopic diseases.
Enteroviruses are transmitted principally orofecally, a
feature suggested to be an important determinant of the
protection provided by certain microbes against atopic
diseases. In adults, seropositivity to orofecal microbes
has been shown to be associated with a reduced preva-
lence of atopic diseases and IgE sensitization [13, 22,
23]. Matricardi et al. reported that Italian atopic adults
had a lower prevalence of hepatitis A virus antibodies
than non-atopic controls, and that the risk of atopy
decreased with a gradient of exposure to foodborne
microbes but not with cumulative exposure to viruses
transmitted via other routes [23]. However, in a nested
case-control study from Scotland, seropositivity to hep-
atitis A was unrelated to the atopic status in adults
[17]. In young children, it has been shown in a longitu-
dinal study that children with salmonellosis had a lower
prevalence of allergic rhinoconjunctivitis and asthma
than children with enteritis due to other microbes [24].
It was also recently reported from a prospective birth
cohort study, that seropositivity to rota- or norovirus
did not protect from IgE sensitization [20].
In our study, the risk of childhood atopy decreased
along with the gradient of exposure to different entero-
virus serotypes, especially to echoviruses. This is in line
with the results from some previous reports showing
the importance of cumulative exposure to microbes [11,
23, 28]. In addition, atopic diseases have quite consis-
tently been observed to be less frequent in children
having several siblings, especially older siblings, most
likely reﬂecting the importance of repeated early micro-
bial contacts [4, 7, 35]. It has also been shown for ente-
roviruses that infants with one or more siblings had
stronger T cell responses to coxsackievirus B4 and poli-
oviruses than single infants [36].
As the immunological events resulting in the Th2-
skewed immune response characteristic for atopic dis-
eases are thought to begin already in neonates or even
in utero, microbial contacts very early in life can be
assumed to be of special importance. In a longitudinal
birth cohort study, children with recurrent episodes of
runny nose before the age of 1 year were less likely to
develop asthma and IgE sensitization than children
experiencing viral infections later in childhood [21].
The protective effect of early viral infections has been
reported from other studies as well [14, 15] but there is
also contradictory data suggesting that early viral
infections might in fact increase the risk for atopy [18,
37, 38]. These conﬂicting data might partly be due to
the heterogeneous nature of atopic diseases, perhaps
modulated by different environmental factors [39, 40].
Previous studies have often relied on parental
reported or physician diagnosed infections, thus detect-
ing only those microbial contacts resulting in a clinical
disease. However, viruses frequently cause subclinical
infections and there are some reports implying a poor
correlation between parental reported infections and
virus serology [7]. It is likely that focusing on clinically
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manifested infections misses a substantial proportion of
microbial contacts. Serological assays, such as the pla-
que neutralization assay, have the advantage of detect-
ing both subclinical and clinically overt infections and
therefore provide a more comprehensive picture of
microbial contacts. We were also able to measure neu-
tralizing antibodies at two distinct time points, thus
providing reliable information about the accumulation
of antibodies to different enterovirus serotypes over
time. In addition, atopy was deﬁned as having both IgE
antibodies against common aeroallergens and a clini-
cally relevant atopic disease, a deﬁnition often used
also in clinical settings. This strict deﬁnition reduces
heterogeneity within the case group, thus facilitating a
more reliable evaluation of risk factors. However, this
also limits our conclusions to IgE positive atopic
patients.
The genetic background of atopic diseases is complex
and a signiﬁcant number of susceptibility genes may be
involved [41]. Our study population was selected from
the cohort of DIPP study children carrying designated
HLA-DQB1 alleles. Sporadic studies have reported some
association between HLA-DQB1 alleles and atopic dis-
eases or IgE sensitization [42, 43] but in other reports,
no association has been observed [44, 45]. A recent
Finnish study found no association between type 1 dia-
betes associated HLA genotypes and atopic sensitization
[46]. Therefore, we do not suspect any bias due to the
genetic selection of the population in this study. Most
importantly, to further rule out the possibility of bias,
the case and control children were matched for their
HLA-DQB1 genotypes on study inclusion. They were
also matched on study inclusion for age and gender.
Other confounding factors analysed and possibly inﬂu-
encing the infectious environment of a child showed no
independent association with atopic diseases.
The precise age of the case child at the time of the
diagnosis of the atopic disease or IgE sensitization was
not available and therefore any conclusions about cau-
sality should be made with caution. However, we did
show a dose-dependent like effect with exposure to dif-
ferent enterovirus serotypes, thus supporting true cau-
sality. Further studies are needed to ﬁnd out whether
this effect is speciﬁc for enteroviruses or if they are
merely surrogate markers for the total burden of infec-
tions or some other environmental factors.
In conclusion, this study shows that cumulative
exposure to enterovirus infections in early childhood is
associated with a reduced risk of atopic diseases. As the
factors inﬂuencing the atopic outcome are still largely
unknown, measures aimed at eliciting the role of differ-
ent environmental factors are urgently needed. Entero-
viruses are suspected to play a role in the pathogenesis
of type 1 diabetes and our research brings new
insight into their possible role in atopic diseases as well.
However, larger prospective studies are needed to
further deﬁne their role in the pathogenesis of atopic
diseases.
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Summary
Background: Prenatal environment has been shown to influence child's risk of ato-
pic diseases. Laboratory‐confirmed data about the role of maternal infections during
pregnancy is scarce.
Objective: The aim of this study was to determine the associations between sero-
logically confirmed maternal infections during pregnancy and atopic disease in the
offspring.
Methods: This was a nested case‐control study within a prospective birth cohort
study. Altogether 202 atopic case children and 333 matched non‐atopic control chil-
dren were included. Atopic outcome was defined as having an atopic disease and
IgE sensitization by the age of 5 years. We analysed serologically acute enterovirus
(EV), influenza virus A (IAV) and Mycoplasma pneumoniae (M. pneumoniae) infections
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during pregnancy, and mother's seropositivity against human cytomegalovirus (CMV)
and Helicobacter pylori.
Results: Maternal EV infection during pregnancy was inversely associated with ato-
pic outcome in the offspring (odds ratio 0.43; 95% confidence interval: 0.23‐0.80,
P = 0.008). Acute IAV or M. pneumoniae infections or seropositivity against CMV or
Helicobacter pylori were not associated with the atopic outcome.
Conclusions and Clinical Relevance: Our results suggest that maternal EV infections
during pregnancy are inversely associated with atopic disease in the offspring. Our
finding provides further support to the previous studies suggesting an important
role of the in utero environment in the development of atopic diseases.
1 | INTRODUCTION
Genetic factors regulate the susceptibility to atopic diseases but the
environment has a significant impact on the disease development.
Atopic diseases usually manifest in childhood stressing the impor-
tance of environmental factors present in very early life.1 Accord-
ingly, extensive data suggest that a variety of environmental
exposures in early childhood can influence the development of ato-
pic diseases.2 Postnatal microbial infections have been among the
most studied factors and several reports have suggested a modula-
tion of the risk of atopic diseases by childhood infections.3-11
Recently, it has become increasingly evident that already the in
utero environment may be important in the development of atopic
diseases.2 A number of prenatal factors, for example, maternal smok-
ing,12 adverse life events13 and pre‐pregnancy overweight14 have
been associated with increased risk of atopic diseases in the off-
spring. In contrast, maternal exposure to farming environment has
been shown to protect the child from atopy.15-17 These findings,
consistent with the framework of hygiene hypothesis, raise the
question about the role of prenatal microbial infections in atopy.
The majority of previous data on prenatal infections are derived from
questionnaire‐based studies, most of which report an increased risk of
atopic disease in children born to mothers with febrile or flu‐like infec-
tions during pregnancy.18 However, questionnaire‐based studies do not
enable the identification of culprit microbes and they may be affected by
recall bias. Applying laboratory assay‐based methods can overcome these
shortcomings but such studies are scarce.19-22 Maternal gastrointestinal
helminth infections have been reported both to inversely associate with
eczema in the offspring20 and not to associate with atopy.19 Intrauterine
bacterial growth at birth as well as chorioamnionitis has been shown to
increase the risk of asthma in the offspring.21,23
We wanted to investigate whether laboratory‐confirmed prenatal
infections are associated with atopic outcome in the offspring. In
addition, we aimed to determine whether microbes with different
infectious and immunological reaction patterns differ in their effect.
Five microbes, featuring gastrointestinal and respiratory pathogens,
as well as microbes causing acute and chronic infections were
included in the current study.
Enteroviruses (EV) can replicate in the gastrointestinal tract, and
they have been linked to atopy in some studies6-8 but not all.4,5 Heli-
cobacter pylori (H. pylori), causing chronic gastric infections and
inflammation, and also considered to be a marker of the general
hygiene level, has been shown to associate with atopy.24 Influenza
virus A (IAV) causes a strong acute systemic infection, whereas cyto-
megalovirus (CMV) persists as a lifelong latent infection. Mycoplasma
pneumoniae (M. pneumoniae) in turn causes often subclinical, chronic
lower respiratory tract infections. We analysed acute gestational EV,
IAV and M. pneumoniae infections by serology from paired serum
samples taken during pregnancy. We estimated the incidence of
acute H. pylori and CMV infections during pregnancy to be very low
in the Finnish population and therefore chose to analyse the pres-
ence of these chronic/latent infections from a single serum sample.
2 | MATERIALS AND METHODS
2.1 | Subjects
The study cohort was derived from the prospective Type 1 Diabetes
Prediction and Prevention (DIPP) study in Finland.25 In the DIPP
study, newborn infants with HLA conferred susceptibility to type 1
diabetes are invited to enter a prospective follow‐up with visits at
the study clinic every 3‐12 months. At each visit, children undergo a
comprehensive interview and clinical examination. Biological samples,
including venous blood samples, are collected according to the study
protocol.
In the present study, we first searched the DIPP database for
children fulfilling the atopic outcome criteria applied: Diagnosis of
bronchial asthma, atopic dermatitis and/or allergic rhinitis and a posi-
tive serum IgE level against aeroallergens at the age of 5 years. Alto-
gether, 202 atopic case children were identified. They were born
between June 1996 and September 2004 in the regions of Tampere
and Oulu cities. Next, we selected 1‐2 non‐atopic control children
for each case child having neither specific IgE against aeroallergens
nor diagnosis of any atopic disease (n = 333). Case and control chil-
dren were matched for gender, region of birth, time of birth (±
3 months) and type 1 diabetes‐related HLA‐DQB1 alleles. In total,
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128 (63%) case children and 207 (62%) control children were boys.
The mean age difference between cases and controls was 45 days
(SD 34 days, range 0‐91 days), and the percentages of case and con-
trol children born each season of the year were equal. Altogether,
9% of children carried the HLA‐DQB1 *02/*03:02 genotype and
91% had the *03:02/x genotype with x referring to other alleles than
*02, *03:01 or *06:02.
Paired serum samples were available from each mother of partic-
ipating children. First sample was taken in prenatal clinics at the end
of the first trimester of pregnancy as a part of a national screening
for infectious diseases. These samples are stored in the nationwide
Finnish Maternity Cohort biobank. The second sample was cord
blood serum from the newborn infant collected according to DIPP
study protocol. The Finnish Maternity Cohort Steering Group at the
National Institute for Health and Welfare approved the use of bio-
bank samples in this study. The DIPP study protocol has been
approved by the ethical committees of the participating university
hospitals (ETL 97193M), and parents have given written informed
consent.
2.2 | IgE antibodies
IgE antibodies against a mixture of common aeroallergens were anal-
ysed from the serum samples taken at the age of 5 years with
ImmunoCAP® enzyme immunoassay (Phadia AB, Uppsala, Sweden).
The multi‐allergen test used (Phadiatop®, Phadia AB, Uppsala, Swe-
den) contains allergens of common pollens, moulds and animals.
Values of ≥0.35 kU/L were considered positive.
2.3 | Microbial analyses
IgG class antibodies against EV, IAV, H. pylori and M. pneumoniae
were measured by applying enzyme immune assays (EIA). IgG class
antibodies against CMV were measured either by applying EIA or by
chemiluminescent immunoassay (CLIA). For CMV, two different
assays were used due to changes in laboratory equipment during the
study period but each case‐control pair was always analysed with
the same method.
Enterovirus, IAV and M. pneumoniae antibodies were analysed
from both first trimester serum samples and cord blood, H. pylori
antibodies from cord blood and CMV antibodies from first trimester
serum samples (n = 146) or cord blood (n = 381), whichever was
available. Samples from case‐control pairs and related first trimester
and cord blood samples were analysed in parallel in the same test
run. All analyses were carried out blind to clinical information.
The assay for EV antibodies employed a synthetic EV peptide
that carries an immunodominant epitope of the viral VP1 protein (se-
quence KEVPALTAVETGAT‐C) as an antigen, as described.26 This
epitope is highly conserved among EVs detecting antibodies against
a wide range of different EV types. For IAV, we used influenza A
virus strain Beijing (BA1231VS, Virion Serion, Würzburg, Germany)
as an antigen, as previously described.27 In brief, microtiter plates
(Nunc Immuno™ plate, Maxisorb, Thermo Fisher Scientific, Waltham,
MA, USA) were coated by the antigens at concentrations 1 μg/mL
for EV and 3 μg/mL for IAV in carbonate buffer (pH 9.4). Serum sam-
ples were analysed diluted 1:1000 in PBS supplemented with 1%
bovine serum albumin, 2% NaCl and 0.05% Tween 20. Serial dilu-
tions for strong positive serum samples were used to reach standard
curve range. Binding of antibodies was documented by using peroxi-
dase‐conjugated anti‐human IgG (P214, Dako, Glostrup, Denmark)
and measuring the absorbance at 490 nm. The results were given in
enzyme immunoassay units (EIU) with reference to negative and
positive control samples. An EIU value of 15 was applied as a cut‐off
level for seropositivity as described.26
Antibodies against H. pylori (Enzygnost® Anti‐Helicobacter pylori/
IgG, Siemens, Marburg, Germany) and antibodies against M. pneumo-
niae (Mycoplasma pneumonia IgG, Labsystems Diagnostics Ltd, Hel-
sinki, Finland) were measured using commercial kits according to the
manufacturers’ instructions. For the analysis of antibodies against
CMV from the first trimester samples, we applied Enzygnost® Anti‐
CMV/IgG EIA kit (Siemens), and for cord blood samples, we used
LIAISON® CMV IgG II CLIA (DiaSorin S.p.A., Saluggia (VC), Italy)
according to the manufacturers’ instructions. We used Siemens BEP
III (Siemens) for processing and calculation of the antibody levels for
the EIAs and LIAISON® XL (DiaSorin S.p.A.) for CLIA.
2.4 | Definition of acute infection
According to the manufacturer's instructions, we defined an acute
M. pneumoniae infection as a 1.6‐fold or higher increase in antibody
level between the maternal first trimester sample and the child's
cord blood sample. For cohesion, we applied the same criteria also
for EV and IAV to indicate an acute infection during pregnancy.
2.5 | Statistical methods
We applied conditional logistic regression analysis to determine the
association between an acute infection during pregnancy (EV, IAV,
M. pneumoniae) or seropositivity (CMV, H. pylori) and atopic disease.
The results are presented as odds ratios (OR) and 95% confidence
intervals (CI) for atopic disease.
Demographic factors are presented in Table 1. We applied condi-
tional regression analysis to estimate the individual association of
each variable with atopic outcome. When an association was
observed, conditional regression analysis was applied to adjust for
these factors. If a value was missing from the case child or all con-
trols in the case‐control group, that case‐control pair/triplet was
excluded from the analyses.
We applied the Bonferroni correction to counteract the problem
of multiple comparisons. As we analysed the association between
acute infection during pregnancy and atopic disease for three
microbes, the Bonferroni correction to control type I error was justi-
fied. After applying the Bonferroni correction, that is, dividing
P = 0.05 by 3, P‐values < 0.017 were regarded as statistically signifi-
cant. Similarly, as seropositivity in a single serum sample was anal-
ysed for two microbes, after applying Bonferroni correction, P‐
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values < 0.025 were statistically significant. Unadjusted P‐values are
presented in the text.
Analyses were performed by using R version 3.3.3 (2017‐03‐06,
The R Foundation for Statistical Computing, https://www.R-project.
org).
3 | RESULTS
Out of the 202 case children, 52 (26%) had asthma, 126 (62%) had
atopic eczema and/or allergic rhinitis, and 24 (12%) had both asthma
and eczema/rhinitis. Specific IgE values varied between 0.36 and
101 kU/L (mean 22.9, median 11). Demographics and their associa-
tions with atopic outcome are presented in Table 1.
A gestational EV infection was observed in 17 (8%) mothers of
the case children and in 53 (16%) mothers of the control children
(Figure 1). M. pneumoniae infection was detected in 14 (7%) vs 37
(11%), and IAV in 26 (13%) vs 43 (13%) mothers of case and control
children, respectively. Seropositivity against CMV was observed in
148 (74%) vs 243 (74%), and H. pylori in 14 (7%) vs 37 (11%) moth-
ers of the case and control children, respectively.
Maternal EV infection during pregnancy was inversely associated
with atopic outcome in the offspring (OR: 0.43; 95% CI: 0.23‐0.80;
P = 0.008). The result remained statistically significant after adjusting
for the relevant confounding factors, that is, older siblings and furry
pets (OR: 0.43; 95% CI: 0.23‐0.81; P = 0.009) (Figure 2). Maternal
IAV or M. pneumoniae infections during pregnancy did not associate
with atopic outcome (OR: 1.05; 95% CI: 0.62‐1.79 and OR: 0.65;
95% CI: 0.34‐1.22, respectively). When all the three microbes were
analysed together, 49 (24%) case mothers and 115 (35%) control
mothers had experienced at least one acute infection during preg-
nancy (OR: 0.60; 95% CI: 0.39‐0.90; P = 0.015).
Maternal seropositivity against CMV or H. pylori was not associ-
ated with atopic outcome in the offspring (OR: 0.99; 95% CI: 0.66‐
1.47 and OR: 0.58; 95% CI: 0.30‐1.12, respectively).
4 | DISCUSSION
The current study suggests that maternal EV infections during preg-
nancy are inversely associated with atopic disease in the offspring.
To our knowledge, EVs or other microbes included have not been
studied in a similar laboratory‐based study setting previously.
We did not find any association between prenatal IAV and
M. pneumoniae infections and atopic outcome. One reason may lie in
the route of infection; IAV and M. pneumoniae are respiratory
microbes, whereas EVs can replicate also in the gut. There are indi-
cations that exposures to enteric pathogens might be particularly
important in the development of atopy and they have been reported
to inversely associate with atopy in some studies28,29 but not in
all.3,11 Our group has previously observed an inverse association
between neutralizing antibodies against echoviruses, belonging to
the enterovirus genus, and atopy.6,7 A recent study showed reduced
anti‐echovirus 30 antibody titres in asthmatic children as compared
with non‐asthmatics,8 which was contrary to a previous rhinovirus
antibody finding.9 In addition, some EVs replicate for relatively long
periods in the gut‐associated lymphoid tissue that is believed to be
important in maintaining immunological tolerance, and EV infections
have been shown to associate with tolerogenic immune responses,
for example, production of IL‐10.30
TABLE 1 Frequencies of potential confounders in case and control children and associations with the study outcome
Case
n = 202 (%)
Control
n = 333 (%) OR (95% CI) P value
Older siblings (yes) 95 (47) 201 (60) 0.60 (0.42‐0.86) 0.006
Furry pets (yes) 58 (29) 146 (44) 0.53 (0.36‐0.78) 0.001
Smoking in pregnancy (yes) 17 (9) 28 (8) 1.00 (0.53‐1.89) 1.00
Maternal education
No secondary 50 (27) 98 (31) ref
Lower secondary 91 (48) 151 (48) 1.01 (0.65‐1.59) 0.96
Higher secondary 48 (25) 63 (20) 1.26 (0.76‐2.11) 0.37
Paternal education
No secondary 86 (46) 144 (48) ref
Lower secondary 46 (25) 88 (30) 0.92 (0.59‐1.44) 0.71
Higher secondary 56 (30) 66 (22) 1.34 (0.85‐2.11) 0.21
Duration of pregnancyab 280 (224‐300) 280 (209‐300) 1.01 (0.99‐1.02) 0.53
Birth weightac 3650 (1910‐4830) 3610 (1660‐5540) 1.00 (1.00‐1.00) 0.27
OR and 95% CI were estimated using conditional logistic analysis. P values below 0.05 are marked in bold.
aValues are medians (minimum and maximum).
bPresented in days.
cPresented in grams.
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Maternal microbial infections during pregnancy can affect the
fetus in several ways. Viral infections can cross the placental barrier
or infect the placenta, which can have severe consequences for the
fetus.31-33 Infections can also affect the fetus through a local inflam-
matory response in the placenta or activation of the maternal sys-
temic immune response.31 For instance, toll‐like receptors (TLRs) are
an important part of innate immunity against viruses and the type of
TLR activated is suggested to depend on the mechanism of replica-
tion used by the virus.34 Maternal exposure to farming has been
shown to increase gene expression of certain TLRs in cord blood,17
and increased expression of some TLR genes at birth has been asso-
ciated with a reduced risk of atopy in the offspring.16 There are also
some indications that maternal infections during pregnancy might
affect the placental microbiome,35 that may in turn influence the
microbial composition of the newborn infant's first intestinal dis-
charge (meconium).36 Differential activation of innate immunity or
changes in the composition of early microbiota might be possible
mechanisms behind the findings in our study and offer an interesting
field for future research.
The strengths of this study include the prospective study setting,
availability of paired serum samples taken during pregnancy and the
strict definition of atopic outcome including both IgE sensitization
and a clinically relevant atopic disease. Most importantly, we relied
on serologically confirmed infections. Many infections, including EV
infections, are asymptomatic or cause only mild clinical presenta-
tions, but serological assays are able to capture both symptomatic
and silent infections. There are only a few previous studies with lab-
oratory‐confirmed infections during pregnancy, and to our
F IGURE 1 The proportion (%) of case
and control mothers with an acute EV, IAV
or M. pneumoniae infection during
pregnancy or seropositivity against CMV
or H. pylori. CMV, cytomegalovirus; EV,
enterovirus; H. pylori, Helicobacter pylori;
IAV, influenza A virus; M. pneumoniae,
Mycoplasma pneumoniae
F IGURE 2 The associations between
acute infections during pregnancy (EV, IAV
and M. pneumoniae) or mother's
seropositivity (CMV and H. pylori) and
atopic disease in the offspring. Results are
presented as OR and 95% CI for each
microbe before and after adjusting for
relevant confounding factors, that is,
having older siblings and contact with furry
animals (adj. OR). CMV, cytomegalovirus;
EV, enterovirus; H. pylori, Helicobacter
pylori; IAV, influenza A virus;
M. pneumoniae, Mycoplasma pneumoniae
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knowledge, the microbes included in the present study have not
been studied previously in detail.19-21 In a study by Murphy et al,22
they used PCR to detect viruses (including EVs and IAVs) from nasal
swabs taken from pregnant asthmatic mothers during a symptomatic
upper respiratory infection. They reported that infants born to moth-
ers with nasal swab positive for any of the tested viruses had an
increased risk of atopy as compared to virus negative mothers. How-
ever, numbers of detected viruses were relatively small; for example,
only 3 EVs detected in 42 samples, and therefore, no conclusions
could be drawn about the role of individual viruses. In the present
study, we used systematic serological screening to detect both
symptomatic and asymptomatic infections as well as infections that
did not coincide with the sample draws.
Acute gestational infections were diagnosed by increases in IgG
levels between maternal serum samples taken at the end of the first
trimester and cord blood serum. The time interval between the two
samples was longer than that usually applied in clinical diagnostics,
but it enabled us to capture acute gestational infections as exten-
sively as possible. IgG responses last usually for several months or
years, but it is possible that some infections may have remained
undetectable due to low or short IgG responses. However, this
should have occurred similarly in both case and control groups. We
used cord blood serum as the second sample, since no maternal
serum was taken at delivery. We have previously shown that EV IgG
levels in cord blood sera correlate well with IgG levels in maternal
sera at the time of delivery.37 We did not measure IgM antibodies,
since IgM antibodies do not cross the placenta and IgM responses
do not develop in all EV infections leading to diminished sensitiv-
ity.38
There are some limitations of our study. First, lack of information
on parental history of atopy prevented us from analysing the results
with respect to different genetic backgrounds. Therefore, the possi-
bility that atopic mothers are genetically less susceptible to EV infec-
tions or that there is another immunological or environmental factor
affected by maternal atopy status, cannot be excluded. Secondly, our
study population was selected for type 1 diabetes‐associated HLA
genotypes, which could affect the generalizability of the results.
Although HLA‐DQ region has been linked to asthma, the genetic
backgrounds of IgE sensitization and atopic diseases are highly poly-
morphic with no strong association to HLA‐DQ region.39 Therefore,
we find it unlikely that the HLA selection would substantially influ-
ence our results. Furthermore, the case and control groups were
matched for the type 1 diabetes‐associated HLA genotypes. It
should also be noted that the prevalence of acute EV infections dur-
ing pregnancy was found to be relatively low, being in line with pre-
vious studies.37,40 As atopic diseases are common in childhood, it is
likely that gestational EV infections are not a major risk‐modifying
factor in atopy. However, the observational design of the present
study makes it difficult to estimate the potential size of this effect
on population level reliably. One should also note that even though
the specificity of the current EV antibody assay has been well docu-
mented,41 we cannot completely exclude the possibility that in some
cases, it could have detected antibodies against other viruses than
EVs. Finally, we have not addressed the mechanisms behind the
inverse association between gestational EV infections and atopy, and
therefore, it is possible that EVs are merely a surrogate marker for a
certain kind of environment mediating the effect observed.
In conclusion, our study suggests that maternal EV infections
during pregnancy are inversely associated with atopic disease in the
offspring. Other included microbes causing acute or chronic infec-
tions lacked this association suggesting that microbes differ in their
capability to affect the processes involved in the development of
atopy. This stresses the importance of microbe‐specific identification
of infections when evaluating their role in the pathogenesis of atopy.
Previous research has shown that postnatal infections play a role in
the development of atopy, and our study adds to this knowledge by
suggesting that microbial exposure already in utero might also be of
importance. Thus, addressing the overall effect of gestational and
postnatal infections on the development of atopy is an important
objective for future studies.
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Abstract
Previous data about the role of viruses in the development of allergic immunoglobulin
E (IgE) sensitization are contradictory. The aim of this study was to determine the
possible associations between exposure to different viruses (rhinovirus, enterovirus,
norovirus, and parechovirus) during the first year of life and IgE sensitization. Viruses
were analyzed from stool samples collected monthly from infants participating in a
prospective birth cohort study. From that study, 244 IgE sensitized case children and
244 nonsensitized control children were identified based on their allergen‐specific
IgE antibody levels at the age of 6, 18, and 36 months. Stool samples (n = 4576) from
the case and control children were screened for the presence of rhinovirus,
enterovirus, norovirus, and parechovirus RNA by reverse transcription quantitative
polymerase chain reaction. The study showed that rhinovirus was the most prevalent
virus detected, present in 921 (20%) samples. None of the viruses were associated
with IgE sensitization in the full cohort but after stratifying by sex, the number of
rhinovirus positive samples was inversely associated with IgE sensitization in boys
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(odds ratio [OR]: 0.81; 95% confidence interval [CI]: 0.69‐0.94; P = 0.006). There was
also a temporal relation between rhinoviruses and IgE sensitization, as rhinovirus
exposure during the first 6 months of life was associated with a reduced risk of
subsequent IgE sensitization in boys (OR: 0.76; 95% CI: 0.6‐0.94; P = 0.016). In
conclusion, early exposure to rhinoviruses was inversely associated with IgE
sensitization but this protective association was restricted to boys.
K E YWORD S
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1 | INTRODUCTION
The rapid increase in the prevalence of atopic diseases during the last
decades highlights the role of environmental factors in the
pathogenesis of these diseases.1 IgE sensitization is a marker of
atopic constitution and is often associated with atopic diseases, such
as asthma, allergic rhinoconjuctivitis, and atopic eczema. Viral
infections are among the potentially interesting environmental
exposures affecting IgE sensitization but current data on the
associations between viruses and IgE sensitization are conflicting.
Some studies have shown virus infections to associate with a lower
risk of IgE sensitization,2,3 whereas others have observed no
associations4,5 or an increased risk.6-8 There are also indications
that viruses may differ in their ability to modulate the risk of IgE
sensitization.3,6,7
The aim of this study was to evaluate the associations between
viral infections in infancy and IgE sensitization. The gut immune
system is important in the development of immunological
tolerance in early childhood and gastrointestinal viruses have
been suggested to be of special significance with regard to atopic
sensitization.9-11 Therefore, viruses known to replicate in the
gastrointestinal tract were selected for the present study:
Enteroviruses (EVs) (family Picornaviridae, genus Enterovirus,
species Enterovirus A‐D), noroviruses (NoVs) (family Caliciviridae,
genus Norovirus) and parechoviruses (HPeVs) (family Picornavir-
idae, genus Parechovirus, species Parechovirus A). Rhinoviruses
(RVs) belong to the Enterovirus genus of the Picornaviridae family,
and they are classified into three species: Rhinovirus A‐C. Wheezing
RV‐infections have been shown to increase the risk of childhood
asthma,12,13 and they have been reported to be present in fecal
samples.14-17 Thereby, also RVs were included in the present
study, even though there is no evidence that they could replicate
in the intestinal mucosa, but are rather passively transmitted from
their replication site in the respiratory mucosa into the gastro-
intestinal tract. In this study, RV, EV, NoV, and HPeV RNA was
analyzed by reverse transcription quantitative polymerase chain
reaction (RT‐qPCR) from stool samples collected monthly during
the first year of life from IgE sensitized and nonsensitized children.
To our knowledge, there are no previous studies about the
associations between viruses detected in stool and risk of IgE
sensitization.
2 | MATERIALS AND METHODS
2.1 | Subjects
The study was carried out as a part of the DIABIMMUNE study
aimed at delineating environmental factors predisposing to immune‐
mediated diseases such as allergies and type 1 diabetes (T1D).18
Human leukocyte antigen (HLA) DR‐DQ genotypes associated with
T1D were screened from the cord blood of 5819 newborns in Finland
and Estonia, as described earlier.18 All children with designated T1D‐
related HLA DR‐DQ genotypes (n = 1139) were invited to participate
in the DIABIMMUNE birth cohort study. Infants were categorized as
having high (DR3‐DQ2/DR4‐DQ8 genotype), moderate (DR4‐DQ8/X
genotype; X = nonprotective allele but not DR3‐DQ2) or slightly
increased (DR3‐DQ2/Y genotype; Y = nonprotective allele but not
DR4‐DQ8) risk for T1D. The study was approved by the local Ethics
Committees (228/13/03/03/2008 and 172/T‐15; 20.08.2008) and
the parents gave their written informed consent.
Altogether 717 out of the 1139 HLA‐eligible newborns participated
in the birth cohort study and 563 children continued until the end of the
follow‐up at 36 months. For the present study, children were selected
according to their IgE levels among these 563 children. In the
DIABIMMUNE study, allergen‐specific IgE levels were measured at 6,
18, and 36 months of age. Altogether 244 (43%) children had positive IgE
values against at least one allergen at the age of 18 and/or 36 months.
These 244 children comprised the case group. Next, 244 non‐IgE
sensitized control children were selected, that is, control children had
negative allergen‐specific IgE levels at 6, 18, and 36 months. Case and
control children were matched for the country of birth, 304 children from
Finland, and 184 children from Estonia, but otherwise, control children
were selected randomly. All children were born between September
2008 andMay 2010. Demographic characteristics of the case and control
groups are presented in Table 1.
2.2 | Virus analyses
Stool samples collected during the first 12 months of life were
systematically screened for the presence of RV, EV, NoV, and HPeV
RNA using RT‐qPCR. Viral RNA was extracted from 10% stool
suspension in HANK’s solution with Qiagen Viral RNA Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions. Viral
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RNA was reverse‐transcribed and amplified according to the
manufacturer’s protocol with QuantiTect Probe Kit (Qiagen) using
primers and labeled probes (Thermo Fisher Scientific, Waltham, MA).
RV was detected by forward primer 5′‐CYA* GCC T*GC GTG GC‐3′
(A* and T* locked nucleic acid primer by Exiqon, Vedbaek, Denmark);
reverse primer GAA ACA CGG ACA CCC AAA GTA and probe VIC‐
TCC TCC GGC CCC TGA ATG YGG C‐TAMRA.19 For EV, the primers
and probes applied were: forward primer: CGG CCC CTG AAT GCG
GCT AA, reverse primer: GAA ACA CGG ACA CCC AAA GTA, probe
1: FAM‐TCT GTG GCG GAA CCG ACT A‐TAMRA, probe 2: FAM‐TCT
GCA GCG GAA CCG ACT A‐TAMRA.20 Primers and probes for NoV
and HPeV detection were applied as described earlier.21 All samples
were tested in three reactions and if any of the reactions were
positive that sample was interpreted as positive for the tested virus.
The samples were analyzed blind to case‐control status of the child.
2.3 | IgE antibodies
Serum samples taken at the age of 6, 18, and 36 months were
analyzed by ImmunoCAP enzyme immunoassay (Thermo Fisher
Scientific, Uppsala, Sweden) for IgE antibodies against cat, dust mite,
birch, timothy, egg, milk, and wheat. IgE antibodies against peanut
were analyzed at the age of 18 and 36 months and antibodies against
dog at 36 months. All analyses were carried out blind to clinical
TABLE 1 Demographic characteristics of the study population
Casea Controlb
n = 244 (%) n = 244 (%) OR (95% CI)
Sex (male) 140 (57) 106 (43) 1.75 (1.22‐2.51)
HLA risk class
DR3‐DQ2/DR4‐DQ8 25 (10) 20 (8) Ref
DR4‐DQ8/xc 98 (40) 110 (45) 0.71 (0.37‐1.36)
DR3‐DQ2/yd 121 (50) 114 (47) 0.85 (0.45‐1.61)
Maternal atopy (yes) 72 (30) 72 (30) 1 (0.68‐1.48)
Paternal atopy (yes) 77 (32) 57 (23) 1.53 (1.02‐2.29)
Parental atopy
Neither 125 (52) 136 (56) Ref
Either or both 117 (48) 108 (44) 1.18 (0.82‐1.68)
Older siblings (yes) 156 (64) 168 (69) 0.8 (0.55‐1.17)
Smoking inside (yes) 16 (7) 11 (5) 1.51 (0.69‐3.34)
Place of Residence
Urban 188 (79) 194 (81) Ref
Rural 41 (17) 39 (16) 1.08 (0.67‐1.76)
Both 9 (4) 8 (3) 1.16 (0.44‐3.07)
Type of Housing
Apartment 82 (34) 93 (38) Ref
Farm 16 (7) 8 (3) 2.27 (0.92‐5.57)
House or row house 118 (49) 127 (53) 1.05 (0.71‐1.55)
More than one type 25 (10) 14 (6) 2.03 (0.99‐4.15)
Pets at home (yes) 106 (44) 98 (41) 1.14 (0.79‐1.63)
Entry in daycare, median (IQR)e 612 (463‐799) 601 (441‐836) 1
Cessation of breastfeeding, median (IQR)e 313 (154‐392) 310 (148‐382) 1
Vaginal delivery (yes) 224 (92) 222 (91) 0.9 (0.48‐1.7)
Duration of pregnancy, d, median (IQR) 281 (274‐286) 282 (274‐287) 0.99 (0.97‐1)
Birth weight, g, median (IQR) 3610 (3228‐3910) 3570 (3295‐3884) 1
Abbreviations: CI, confidence interval; HLA, human leukocyte antigen; IgE, immunoglobulin E; IQR, interquartile range; OR, odds ratio.
The association between each factor and IgE sensitization was estimated by logistic regression analysis (univariate analysis). The results are presented as
OR and 95% CI for IgE sensitization.
aCase, a child with at least one positive allergen specific IgE level at 18 and/or 36 months.
bControl, a child with negative allergen specific IgE levels at 6, 18, and 36 months.
cx, not DR3‐DQ2 or a haplotype associated with protection against type 1 diabetes (T1D).
dy, not DR4‐DQ8 or a haplotype associated with protection against T1D.
eAge of the child in days.
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information. Values greater than or equal to 0.35 kU/L were
considered positive.
2.4 | Statistical methods
Logistic regression analysis was applied to estimate odds ratios (ORs)
and corresponding 95% confidence intervals (CIs) for IgE sensitiza-
tion. The association between virus exposure and IgE sensitization
was evaluated by calculating the number of virus‐positive stool
samples in each child during the follow‐up and comparing the number
of positive samples in case and control children. After stratification
by sex, this comparison was made between male cases and controls
and accordingly, between female cases and controls. OR value
expresses an estimation of how much each virus‐positive sample
affects the risk to become IgE sensitized. This estimate was
calculated for each virus separately. Additionally, the number of
case and control children having at least one virus positive sample
during the follow‐up was calculated for each of the four viruses and
logistic regression analysis was applied to estimate the ORs and 95%
CIs for IgE sensitization.
IgE values were measured at 6, 18, and 36 months of age and
viruses were analyzed from stool samples collected monthly during
the first year of life (Figure 1). To observe temporal relations
between virus exposure and IgE sensitization, case children were
divided into two groups; late sensitized (n = 162) and early sensitized
(n = 57) (IgE values at 6 months were missing from 25 cases and 10
controls). The late sensitized group comprised of case children who
were IgE negative at 6 months but became IgE positive later during
the follow‐up, and the early sensitized children were case children
who were IgE positive already at 6 months. In the late and early
sensitized groups, the associations between virus exposure and IgE
sensitization were determined by calculating the number of virus‐
positive samples during the first 6 months of follow‐up.
Children were also classified according to the nature of their IgE
sensitization: children sensitized against at least one aeroallergen
(cat, dog, dust mite, birch, timothy) were classified as “aeroallergen
sensitized” (n = 104) and children sensitized against at least one
dietary allergen (egg, milk, wheat, peanut) comprised the group of
“dietary sensitized” (n = 214). Depending on their sensitization
profile, case children could belong to one or both of these groups
(Table S1).
Demographic characteristics of the study population are shown in
Table 1. These data included: T1D‐related HLA risk classes, parental
atopy (having at least one of the following: asthma, hay fever/allergic
rhinitis, or atopic dermatitis), having older siblings, smoking inside,
place of residence (“urban”: city center or residential areas, “rural”:
population centers/sparsely populated areas, and “both”: change
between the categories during the follow‐up), type of housing, having
furry pets at home, child’s age at the beginning of daycare, duration
of breastfeeding (including partial breastfeeding), route of delivery,
duration of pregnancy, and birth weight. These factors were also
addressed as possible confounding factors. Univariate logistic
F IGURE 1 Timeline of the study. Allergen‐specific IgE levels were measured at 6, 18, and 36 months. Stool samples were collected monthly
during the first year of follow‐up. Definition of an atopic case child was IgE sensitization at 18 and/or 36 months. These case children (n = 244)
were divided into early sensitized and late sensitized according to their IgE levels at 6 months (data was missing from 25 case children). Control
children were IgE negative at 6, 18, and 36 months (data at 6 months was missing from 10 control children). IgE, immunoglobulin E; RT‐PCR,
reverse transcription polymerase chain reaction
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regression analysis was applied to estimate the ORs and 95% CIs for
each factor (Table 1). When a significant effect on IgE sensitization
was observed, logistic regression analysis was used to adjust for this
factor. Unadjusted P values are presented in the text.
The Bonferroni correction was applied to counteract the problem
of multiple comparisons. As the association between virus exposure
and IgE sensitization was analyzed for four different viruses, the
Bonferroni correction to control type I error was justified. After
Bonferroni correction, P < 0.013 was considered statistically
significant.
Analyses were performed by using R version 3.3.3 (2017‐03‐06, The
R Foundation for Statistical Computing, https://www.R‐project.org).
3 | RESULTS
Altogether 4576 stool samples were analyzed, 2258 from case
children and 2318 from control children. The number of stool
samples available for analysis each month is presented in Table S2.
RV was the most prevalent virus detected during the first year of life,
with 921 of 4576 (20%) positive samples. The number of positive
samples for EV, NoV, and HPeV was 203 (4%), 243 (5%), and 194
(4%), respectively. RVs were prominent already during the first 6
months of life, whereas the prevalence of EVs, NoVs, and HPeVs
started to increase later (Figure 2).
The number of children having at least one virus‐positive sample
during the follow‐up did not differ between case and control children
for any of the viruses. For RVs: 184 (75%) case children vs 187 (77%)
control children had at least one positive sample (OR: 0.93; 95% CI:
0.62‐1.42; P = 0.75), for EVs: 57 (23%) case children vs 51 (21%)
control children (OR: 1.15; 95% CI: 0.75‐1.77; P = 0.51), for NoVs: 69
(28%) case children vs 83 (34%) control children (OR: 0.76; 95% CI:
0.52‐1.12; P = 0.17), and for HPeVs: 62 (25%) case children vs 66
(27%) control children (OR: 0.92; 95% CI: 0.61‐1.38; P = 0.68).
The number of virus‐positive stool samples during the follow‐up did
not differ between case and control children for any of the viruses in the
full cohort (Table 2). However, after stratifying the study cohort by sex,
the number of RV‐positive samples was inversely associated with IgE
sensitization in boys (OR: 0.81; 95% CI: 0.69‐0.94; P=0.006) but not in
girls (OR: 1.02; 95% CI: 0.87‐1.19; P=0.83). In boys, 104 (74%) case
children had at least one RV‐positive stool sample vs 89 (84%) control
children. In girls, 80 (77%) case children had at least one RV‐positive
sample vs 98 (71%) in control children. Sex did not influence the overall
prevalence of RV infections, as the number of RV‐positive samples did
not differ between boys and girls: 485 (21%) vs 436 (19%), respectively.
Stratification by sex did not have an effect on the associations observed
with EV, NoV, or HPeV (Table 2). The demographic characteristics
stratified by sex are presented in Tables S3 and S4. The number of case
and control children with the positive paternal history of atopy differed
statistically significantly in the full cohort and among girls. Adjusting for
this confounder did not affect the results.
The sex‐based difference in the association between RV exposure
and IgE sensitization was observed also in the late and early
sensitized groups (definitions in Table S1). In boys, the number of
RV‐positive samples during the first 6 months of life was inversely
associated with subsequent IgE sensitization (late sensitized group):
OR: 0.76; 95% CI: 0.6‐0.94; P = 0.016, and simultaneous IgE
sensitization (early sensitized group): OR: 0.6; 95% CI: 0.39‐0.85;
P = 0.008. In girls, no associations were observed. In addition, an
inverse association between RV positivity and IgE sensitization was
F IGURE 2 The percentage of reverse transcription quantitative
polymerase chain reaction (RT‐qPCR)‐positive stool samples for each
virus during the 12‐month follow‐up. The number of stool samples
available for analysis each month is presented in Table S2. RT‐qPCR,
quntitative reverse‐transcription polymerase chain reaction
TABLE 2 The number of virus‐positive samples and associations
with IgE sensitization
Case
n (%)
Control
n (%) OR (95% CI) P value
Rhinovirus
Full cohort 429 (19) 492 (21) 0.91 (0.82‐1.01)0.09
Boys 239 (19) 246 (24) 0.81 (0.69‐0.94)0.006
Girls 190 (19) 246 (19) 1.02 (0.87‐1.19)0.83
Enterovirus
Full cohort 103 (5) 100 (4) 1.01 (0.80‐1.20)0.89
Boys 52 (4) 42 (4) 0.97 (0.70‐1.30)0.83
Girls 51 (5) 58 (5) 1.07 (0.80‐1.40)0.60
Norovirus
Full cohort 111 (5) 132 (6) 0.90 (0.70‐1.10)0.29
Boys 58 (5) 59 (6) 0.80 (0.60‐1.10)0.19
Girls 53 (5) 73 (6) 1.00 (0.70‐1.30)0.88
Parechovirus
Full cohort 92 (4) 102 (4) 0.90 (0.70‐1.20)0.55
Boys 56 (4) 51 (5) 0.90 (0.60‐1.21)0.43
Girls 36 (4) 51 (4) 1.00 (0.70‐1.37)0.80
Abbreviations: CI, confidence interval; IgE, immunoglobulin E; OR, odds
ratio.
Each virus was analyzed from stool samples collected during the first year
of life (n = 4576). The association between the number of virus‐positive
samples and IgE sensitization is presented as OR and 95% CI.
P values below 0.05 are marked bold.
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detected in both aeroallergen and dietary sensitized boys (OR: 0.78;
95% CI: 0.63‐0.94; P = 0.014 and OR: 0.82; 95% CI: 0.69‐0.95;
P = 0.012, respectively), whereas no association was observed in girls
(Figure 3). The number of samples positive for EV, NoV, or HPeV was
not associated with IgE sensitization in any of the case categories
(data are not shown).
4 | DISCUSSION
The results from this prospective birth cohort study reinforce
previous data that RVs are frequent in stool in infancy. The study
demonstrates for the first time that RVs detected in stool are
inversely associated with IgE sensitization. The study also reports a
novel sex‐based difference, as the inverse association between RV
exposure and IgE sensitization was only observed in boys. Further-
more, RV detection during the first 6 months of life was inversely
associated with subsequent IgE sensitization in boys. This temporal
order, that is, RV exposure preceding IgE sensitization, suggests that
RV infections in early life may act as protective environmental
factors against IgE sensitization, but the effect seems to be
associated with sex.
Previous studies have shown that RVs, although considered
respiratory pathogens are detected frequently in stool in child-
hood.14-17 The reasons for this phenomenon are not clear. RVs infect
primarily nasopharyngeal epithelia, and RVs passing through the
gastrointestinal tract is the most plausible explanation for detecting
RV in the stool. RVs are also acid sensitive and thereby thought to
degrade in the acidic gastric environment. One explanation for the
high detection rate of RVs in stool in early life might lie in the
relatively high gastric pH in infancy that might lead to diminished
degradation of RV RNA in the stomach.22 The prospective study
setting in the present study allowed also detecting temporal changes
in the virus prevalence; the number of RV‐positive stool samples was
high in early infancy and gradually decreased during the first year of
life. The observed decreasing RV prevalence with age may well be
F IGURE 3 Associations between rhinovirus‐positive stool samples and IgE sensitization in the full cohort and among boys and girls. Results
are expressed as odds ratios (ORs) with 95% confidence intervals (CIs) for IgE sensitization. Aero, case children sensitized against aeroallergens;
All, all case children, that is, children IgE sensitized at 18 and/or 36 months, (n = 244, 140 boys and 104 girls); Diet, case children sensitized
against dietary allergens; Early, case children sensitized already 6 months; Late, case children sensitized at 18 and/or 36 months but not at 6
months
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explained by a steep decrease in gastric pH during the first year of
life, observed by Nagita et al.22 There is also an in vitro study
showing that acidic environment selects rapidly RV strains carrying a
point mutation in the capsid protein conferring resistance to
inactivation in low pH.23 In addition to acid sensitivity, RVs have
been thought to replicate optimally at temperatures of 33°C to 34°C
equaling that of the upper airways. However, Papadopoulos et al24
reported only minimal differences in the replication capacity of some
RVs between temperatures of 33°C and 37°C. Even though not
addressed in the current study, it may, therefore, be that some RV
types also retain their viability in the gut, as suggested by the results
showing RVs replicating upon cultivation after isolation from
stool.15,16
RV‐induced wheezing has been shown to increase the risk of
childhood asthma25 but there are fewer data about the role of RVs in
IgE sensitization.4,7,26 Jartti et al7 reported a positive association
between wheezing RV infection and IgE sensitization in a cross‐
sectional study setting. Later, a prospective study showed that
aeroallergen sensitization predisposed children to RV‐induced
wheezing, but the opposite was not seen.4 It might also be important
to notice, that most previous studies have relied on samples taken
during symptomatic RV infections, especially RV‐induced wheezing,
with few data derived from systematic sample collection regardless
of symptoms.13,27 In fact, there are indications that asymptomatic or
mild RV infections might differ from severe ones in relation to atopy.
Jackson et al13 reported severe wheezing RV infections to increase
the risk of asthma but found no association between asthma and RVs
detected from nasal samples during prescheduled visits. In accor-
dance, picornaviruses, including RVs, detected from routine nasal
samples taken at four distinct time points during the first year of life,
were shown not to associate with atopic sensitization.27 Thus, it is
possible that the association between RVs and wheezing episodes is
characteristic for children who already have airway hyperreactivity,
while RV infections that occur in early infancy may reduce the risk of
IgE sensitization. The latter association may be more difficult to
detect since it requires prospective birth cohort studies and depends
on the sex of the child.
The sex‐based difference observed is interesting, since suscept-
ibility to a wide range of infections and immune‐mediated diseases is
influenced by sex. In general, boys have increased susceptibility to
many virus infections whereas girls often develop stronger immune
responses resulting in lower prevalence and intensity of infec-
tions.28,29 There are not much prior data about possible sex‐based
differences in RV infections. Boys were shown to have more
moderate‐to‐severe RV illnesses during early childhood as well as
higher interferon‐γ (IFN‐γ) responses than girls did.30 In addition, an
animal study showed that early RV infections contributed to the
development of allergen‐induced lung disease in the female, but not
in male mice.31 In contrast, there is a well‐known sex‐based
difference in the prevalence of IgE sensitization and childhood
asthma with male sex predisposing to both.30,32,33 The reasons for
the male dominance in susceptibility to virus infections and atopy are
not known but diverse and widespread effects of sex hormones
probably play a role.34
Most previous birth cohorts on atopy have included children
genetically at high risk for atopy. There is a strong and hetero-
geneous genetic component in childhood asthma35 and maternal
atopy has also been reported to increase the risk of severe RV
bronchiolitis.36 Furthermore, variants at the 17q21 gene locus have
been shown to associate with asthma especially in children
presenting with RV‐associated wheezing illness.37 It is, therefore,
possible that in genetically selected cohorts, children are not only at
higher risk for asthma but also for severe RV infections, which could
contribute to the previously observed positive associations between
RV infections and asthma. In contrast, the study population in the
present study was selected for T1D‐associated HLA types. There are
some data linking HLA‐DQ region to asthma, and HLA‐DRB1 has also
been linked to IgE sensitization.38 However, as the genetic back-
ground of atopy is highly polymorphic and it has been estimated that
HLA‐DRB1 locus only accounts for 2% to 3% of the variation in
specific IgE titers,38 it is unlikely that the HLA selection would have
substantially influenced our results. Furthermore, the distribution of
HLA‐DR/DQ types was similar in case and control groups.
RV infections are generally diagnosed by RT‐PCR assays
targeting the 5′ noncoding region (5′‐NCR) of the RV genome.39
Due to sequence similarities in the 5′NCR between RVs and EVs, it is
known that some RV PCR assays detect also EVs thereby reducing
the specificity of the assays. In a study by Lu et al,19 the RV RT‐PCR
assay applied in the present study was shown to amplify all of the
100 RV prototype strains and 85 field isolate strains included in their
sensitivity and specificity analysis. The assay did not amplify 34 of the
48 EV types included, while 14 EV types gave weakly positive
reactions when present in the sample in high titers.19 In addition, the
RV RT‐PCR primers and probes applied in the present study were
included in the study by Faux et al40 comparing the usefulness of
different PCR primers in detecting RV infections. The RV RT‐PCR
assay in question, amplified 20 out of the 29 RV types including types
from all RV species (Rhinovirus A‐C) and most importantly, the assay
did not amplify any of the EVs included.40 These studies confirm that
the RV RT‐PCR primers and probes applied in the current study are
both sensitive and specific. However, the possibility that some RVs
might have been missed or that there might be some low‐degree
cross‐detection between RVs and EVs cannot be excluded.
In the current study, no genotyping of RVs was performed.
Thereby, the results do not indicate whether consecutive RV‐positive
stool samples represent a single prolonged infection or separate
independent infections. However, in a former study by our group, 43
different RV types were identified among the 63 RV‐positive stool
samples sequenced and only once was the same genotype detected in
two sequential samples.15 This finding by Honkanen et al is an
illustration of the high genetic diversity characteristic for RVs and
suggests that shedding of RVs in the stool is short‐term. These
previous results support the current interpretation that each
RV‐positive sample represents individual exposure and the high
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frequency of RVs in stool probably reflects the diversity of
circulating RVs.
The allergen panel applied in the IgE analysis was defined
according to local sensitization patterns against dietary and aero-
allergens.41 It includes the majority of the relevant allergens and is
thereby likely to detect most IgE sensitized children in this age group.
However, some children sensitized only to some of the more
uncommon allergens might have been missed but the number of
these children is estimated to be low.
In conclusion, this study provides new insights into the role of
different viruses, especially RVs, in atopic sensitization. Data based
on monthly collection of stool samples demonstrated that RVs are
commonly present in young infants’ gut and that this RV exposure
was associated with a reduced risk of IgE sensitization in boys. The
findings suggest that RVs might have a more versatile role in the
development of atopy than previously perceived. We hypothesize
that early RV exposure could serve a beneficial function in driving
postnatal maturation of the immune competence, thereby reducing
the risk of allergic sensitization. In addition, the clear sex‐based
difference in the effect of RVs observed emphasizes the importance
of exploring the impact of sex also in future studies aimed at
elucidating the mechanisms of atopic disease.
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